Family of large biological molecules
POPULARITY
Categories
108 episodes with RNA
65 episodes with RNA
76 episodes with RNA
25 episodes with RNA
142 episodes with RNA
27 episodes with RNA
28 episodes with RNA
42 episodes with RNA
26 episodes with RNA
14 episodes with RNA
15 episodes with RNA
19 episodes with RNA
10 episodes with RNA
24 episodes with RNA
11 episodes with RNA
36 episodes with RNA
11 episodes with RNA
13 episodes with RNA
9 episodes with RNA
10 episodes with RNA
28 episodes with RNA
16 episodes with RNA
16 episodes with RNA
11 episodes with RNA
7 episodes with RNA
6 episodes with RNA
8 episodes with RNA
7 episodes with RNA
9 episodes with RNA
11 episodes with RNA
11 episodes with RNA
9 episodes with RNA
6 episodes with RNA
12 episodes with RNA
14 episodes with RNA
18 episodes with RNA
6 episodes with RNA
4 episodes with RNA
10 episodes with RNA
162 episodes with RNA
4 episodes with RNA
7 episodes with RNA
5 episodes with RNA
4 episodes with RNA
12 episodes with RNA
10 episodes with RNA
150 episodes with RNA
11 episodes with RNA
5 episodes with RNA
8 episodes with RNA
8 episodes with RNA
5 episodes with RNA
7 episodes with RNA
8 episodes with RNA
6 episodes with RNA
10 episodes with RNA
6 episodes with RNA
4 episodes with RNA
6 episodes with RNA
7 episodes with RNA
6 episodes with RNA
7 episodes with RNA
8 episodes with RNA
5 episodes with RNA
3 episodes with RNA
7 episodes with RNA
6 episodes with RNA
3 episodes with RNA
15 episodes with RNA
4 episodes with RNA
5 episodes with RNA
8 episodes with RNA
4 episodes with RNA
5 episodes with RNA
7 episodes with RNA
8 episodes with RNA
8 episodes with RNA
3 episodes with RNA
7 episodes with RNA
4 episodes with RNA
4 episodes with RNA
3 episodes with RNA
7 episodes with RNA
8 episodes with RNA
7 episodes with RNA
10 episodes with RNA
10 episodes with RNA
10 episodes with RNA
9 episodes with RNA
6 episodes with RNA
7 episodes with RNA
19 episodes with RNA
5 episodes with RNA
14 episodes with RNA
5 episodes with RNA
3 episodes with RNA
5 episodes with RNA
3 episodes with RNA
4 episodes with RNA
10 episodes with RNA
6 episodes with RNA
3 episodes with RNA
5 episodes with RNA
4 episodes with RNA
4 episodes with RNA
3 episodes with RNA
5 episodes with RNA
4 episodes with RNA
5 episodes with RNA
4 episodes with RNA
5 episodes with RNA
5 episodes with RNA
5 episodes with RNA
7 episodes with RNA
10 episodes with RNA
10 episodes with RNA
9 episodes with RNA
3 episodes with RNA
12 episodes with RNA
6 episodes with RNA
3 episodes with RNA
4 episodes with RNA
4 episodes with RNA
3 episodes with RNA
2 episodes with RNA
3 episodes with RNA
3 episodes with RNA
8 episodes with RNA
5 episodes with RNA
5 episodes with RNA
4 episodes with RNA
3 episodes with RNA
4 episodes with RNA
4 episodes with RNA
4 episodes with RNA
3 episodes with RNA
3 episodes with RNA
3 episodes with RNA
6 episodes with RNA
4 episodes with RNA
4 episodes with RNA
3 episodes with RNA
3 episodes with RNA
3 episodes with RNA
3 episodes with RNA
4 episodes with RNA
3 episodes with RNA
8 episodes with RNA
3 episodes with RNA
3 episodes with RNA
2 episodes with RNA
4 episodes with RNA
3 episodes with RNA
Nature: Asteroids, antibiotics and ants: a year of remarkable scienceIn this episode:1:58 Evidence of ancient brine on an asteroidSamples taken from the asteroid Bennu by NASA's OSIRIS-REx spacecraft suggest the parent body it originated from is likely to have contained salty, subsurface water. This finding provides insights into the chemistry of the early Solar System, and suggests that brines might have been an important place where pre-biotic molecules were formed.News & Views: Asteroid Bennu contains salts from ancient brineNature Podcast: Asteroid Bennu contains building blocks of life08:01 How gene expression doesn't always reflect a cell's functionCells are often grouped into categories according to the RNA molecules they produce. However a study of zebrafish (Danio rerio) brains revealed that cells can be functionally diverse even if they appear molecularly similar. This finding adds more nuance to how a cell's ‘type' is ultimately defined.News & Views: Does a cell's gene expression always reflect its function?12:01 The disproportionate mortality risks of extreme rainfallAn assessment of death rates in India's coastal megacity of Mumbai revealed that the impact of extreme rainfall events will be highest for women, young children and residents of informal settlements. This situation is likely to become more pronounced as a result of climate change.News & Views: Extreme rainfall poses the biggest risk to Mumbai's most vulnerable people14:46 An AI-designed underwater glueInspired by animals like barnacles and aided by machine learning, researchers have developed a super-sticky compound that works as an underwater adhesive. To demonstrate its properties, researchers applied it to a rubber duck, which stuck firmly to a rock on a beach despite being battered by the sea.News & Views: AI learns from nature to design super-adhesive gels that work underwaterNature Podcast: Underwater glue shows its sticking power in rubber duck test Hosted on Acast. See acast.com/privacy for more information.
The origin of life is one of the biggest challenges to secular scientists. Hear a leading expert expound upon a myriad of reasons why! There will be some work for these two. He shared his screen and showed some videos, but he sent me links to use that should be better (i.e., cut-out the live version and insert the video taken from the links he's giving us. See below my signature for those links).Also, his mic went out a number of times and he had to fix it quickly. That should all be edited out. Let me know if you have any questions.1) from Verisasium YouTube Channel, "The most controversial idea in biology":https://youtube.com/clip/UgkxDPCtBoV57kP7N3sy9BoBwKzaWOpKqk_c?si=iXXH4u0s19BVFOWo2) From Long Story Short, "Debunking popular science videos on the origin of life and RNA world"https://youtu.be/dKoWpWGS-zY?si=Ls8R0L6auKsASnFF from 4:28.6 to 4:50.93) From Long Story Short, "Surviving the Daily DNA Apocalypse"https://youtube.com/clip/UgkxmsQ_bxpMaYtHqtjeDsrkkqEONYRNG5Yo?si=wg3LPhwxdR8qUPGz4) From Long Story Short, "Surviving the Daily DNA Apocalypse"https://youtube.com/clip/UgkxrdEiIUifweDIR99ro_Z0Oe_P7D5N-UqE?si=io7tIULpVwLXQVC25) From Long Story Short, "Awkward truths about the origin of life: Energy and metabolism"https://youtube.com/clip/UgkxDfnmez63NDacsa2jp0S4o_QDdobuo8t1?si=y5R36fqCcVuLH8qU6) From Long Story Short, "Awkward truths about the origin of life: Energy and metabolism"https://youtube.com/clip/UgkxhE4pJPHFRDfkkGSlG_qTuYKulzGRxr59?si=9z5X5r9wDMWazKwM
We're pleased to feature Steve Brown in this episode of Wolf Greenfield's Alumni Spotlight series. He was previously a technology specialist in Wolf Greenfield's Biotechnology Practice. Today, Steve serves as Associate General Counsel at Orna Therapeutics. Orna is reshaping RNA therapeutics to open an entirely new world of possibilities in the treatment of disease.Here are some highlights from Steve's turn in the Alumni Spotlight on IP Talk with Wolf Greenfield.00:47 - Steve's current responsibilities at Orna02:19 - Making the transition from a law firm into corporate roles03:26 - An overview of Orna Therapeutics05:18 - Steve's favorite memory of Wolf Greenfield07:25 - When Steve thinks of his time at Wolf Greenfield, what comes to mind?09:10 - Steve's dream travel destination10:09 - His favorite movie###
SpaceTime with Stuart Gary | Astronomy, Space & Science News
SpaceTime with Stuart Gary - Series 28 Episode 145In this episode of SpaceTime, we explore groundbreaking discoveries that deepen our understanding of the origins of life and the dynamics of our galaxy.Sugars and Stardust: Insights from Asteroid BennuNASA's Osiris Rex mission has returned samples from the asteroid Bennu, revealing the presence of biologically essential sugars, including ribose and glucose, along with a unique gum-like substance never before seen in astromaterials. These findings, published in Nature Geoscience and Nature Astronomy, suggest that the building blocks for life were widespread throughout the early solar system. The discovery of ribose supports the RNA world hypothesis, indicating that RNA might have been the first genetic material. Additionally, the presence of glucose hints at the early energy sources available for life on Earth.Stars Defying the Black HoleAstronomers have observed numerous stars in stable orbits around Sagittarius A, the supermassive black hole at the center of our galaxy. This discovery, reported in Astronomy and Astrophysics, challenges previous assumptions that these objects were merely clouds of dust on a collision course with destruction. Instead, the new data from the ERIS Enhanced Resolution Imager and Spectrograph reveals a dynamic and stable environment around the black hole, providing a unique laboratory for studying interactions between black holes and stars.Martian Mystery Solved?A new radar technique employed by NASA's Mars Reconnaissance Orbiter has cast doubt on the existence of a suspected underground lake beneath the Martian South Pole ice cap. Initial signals that suggested the presence of liquid water have been reinterpreted as possibly being layers of rock and dust. This innovative approach opens new avenues for investigating subsurface resources on Mars, which could have significant implications for future exploration.www.spacetimewithstuartgary.com✍️ Episode ReferencesNature GeoscienceNature AstronomyAstronomy and AstrophysicsGeophysical Research LettersBecome a supporter of this podcast: https://www.spreaker.com/podcast/spacetime-your-guide-to-space-astronomy--2458531/support.
As part of our official DealFlow Discovery Conference Interview Series, produced by Mission Matters, along with our partner DealFlow Events, we're showcasing the innovative companies presenting at the DealFlow Discovery Conference and the executives behind them. Today's spotlight features Robert Bitterman, CEO & President of Phio Pharmaceuticals, who discusses how the company's INTASYL™ RNA platform is engineered to reactivate immune cells directly within the tumor microenvironment — opening the door to safer, more targeted cancer therapies. In this episode, Adam Torres interviews Robert Bitterman, CEO and President of Phio Pharmaceuticals, about the company's mission to create new pathways toward a cancer-free future. Robert explains how Phio's INTASYL™ platform uses targeted RNA technology to reactivate immune cells inside the tumor microenvironment, potentially offering a safer and more effective approach to treating cutaneous squamous cell carcinoma. He also shares early clinical data, the next steps toward pivotal trials, and why education and innovation remain at the heart of Phio's work. Follow Adam on Instagram at https://www.instagram.com/askadamtorres/ for up to date information on book releases and tour schedule. Apply to be a guest on our podcast: https://missionmatters.lpages.co/podcastguest/ Visit our website: https://missionmatters.com/ More FREE content from Mission Matters here: https://linktr.ee/missionmattersmedia Learn more about your ad choices. Visit podcastchoices.com/adchoices
Janelle Connell is a registered dietician and personalized nutrition expert working with Viome to help people discover how to properly eat based on their individual microbiome and gene expression.Grant Antoine, ND brings his expertise in medicine and nutrition to unlock the connections between what is happening in the microbiome and the effects we see play out in our body over time.Key takeaways from this discussion:Understanding microbiome activity rather than just composition is crucial for personalized health approachesRNA analysis reveals microbe activity rather than just presence, providing more actionable health insightsThis technology allows for personalized food and supplement recommendations based on individual microbiome activityEarly detection and prevention through microbiome testing can help delay or prevent chronic diseaseFiber is essential for feeding beneficial gut microbesPersonalized nutrition should consider individual glycemic responses to foodsSupporting the microbiome during and after antibiotic use is important for healthPersonalized supplement formulations are created based on individual test resultsViome uses RNA sequencing technology to analyze microbiome activity rather than just composition, providing personalized nutrition recommendations. Click this link viome.com to receive a $50 discount on your first test kit. Visit ConfidenceThroughHealth.com to find discounts to some of our favorite products.Follow me via All In Health and Wellness on Facebook or Instagram.Find my books on Amazon: No More Sugar Coating: Finding Your Happiness in a Crowded World and Confidence Through Health: Live the Healthy Lifestyle God DesignedProduction credit: Social Media Cowboys
Superpowers for Good should not be considered investment advice. Seek counsel before making investment decisions. When you purchase an item, launch a campaign or create an investment account after clicking a link here, we may earn a fee. Engage to support our work.Watch the show on television by downloading the e360tv channel app to your Roku, LG or AmazonFireTV. You can also see it on YouTube.Devin: What is your superpower?Dr. Dale: When I run into a problem, the first thing I have to do is tell myself, don't be afraid. You've solved other problems in the past. You can solve this one.Millions of people worldwide face the devastating impact of cancer, with countless lives lost each year to tumors that no longer respond to existing treatments. Dr. Dale Walker, Co-founder and CEO of The Burlington HC Research Group (BHCRG), is working to change that narrative with her groundbreaking development of a new family of anti-cancer drugs. These drugs have the potential to revolutionize treatment for cancers that have become resistant to current therapies.“We tested our drugs against 15 human cancer cell lines, representative of seven different tissues, and the drug works against all of them,” Dale explained. In the U.S. alone, over 600,000 people die annually from cancer, often because their tumors no longer respond to treatment. Dale's research offers a glimmer of hope for patients and their families.Unlike traditional drug development that focuses on a single compound, Dale and her team have created a family of drugs—called BRG drugs—by combining two FDA-approved ingredients in a novel way. These drugs not only enhance the effectiveness of existing cancer treatments but also demonstrate the ability to kill nearly all cancer cells after a single dose in preclinical studies. “Most anti-cancer agents just slow tumor growth. Ours hit both marks—killing tumor cells at a safe dose level,” she said.With such promising results, Dale and her husband Vernon, who co-leads the research, are pushing forward. However, taking these drugs through the necessary safety and efficacy tests requires significant funding. To accelerate progress, BHCRG is raising capital through a regulated crowdfunding campaign on the FundingHope platform. Crowdfunding offers a faster alternative to traditional funding sources, enabling the Walkers to bypass lengthy government grant timelines.“Crowdfunding is a lifeline. We have family members and friends with cancer. We can't wait years,” Dale shared. For investors, the opportunity to back a potential game-changing cancer therapy is compelling, both for its societal impact and long-term financial potential.Dale's passion and perseverance shine through in her work. Her innovative approach to drug development could save countless lives. Supporting her mission on Funding Hope isn't just an investment in a company—it's an investment in hope.tl;dr:Dale Walker shares her innovative work on new anti-cancer drugs targeting resistant tumors.BHCRG's BRG drugs show promising preclinical results, killing almost all tumor cells with one dose.Dale explains crowdfunding's role in accelerating drug development for life-saving cancer treatments.She discusses perseverance as her superpower, solving challenges by embracing and examining problems.Today's episode highlights how crowdfunding enables investors to support impactful innovations in healthcare.How to Develop Perseverance in Problem-Solving As a SuperpowerDale's superpower is her extraordinary ability to solve complex problems and persevere through challenges. In today's episode, she explained, “When I run into a problem, the first thing I have to do is tell myself, don't be afraid. You've solved other problems in the past. You can solve this one.” Dale emphasized that problems often contain valuable information that leads to solutions, encouraging others to examine challenges closely rather than avoiding them.After discovering that an FDA-approved drug had antiviral activity, Dale faced a seemingly insurmountable challenge: making the drug work effectively in people. “I thought, I will not be able to solve this problem. It's too hard,” she admitted. Yet, she persevered, combining the drug with another FDA-approved ingredient. This breakthrough created the BRG family of cancer drugs, which kill nearly all cancer cells in preclinical studies after a single dose. Her ability to persist through doubt and difficulty exemplifies her superpower.Tips for Developing Perseverance in Problem-Solving:Acknowledge Your Strengths: Remind yourself that you've solved tough problems before and can do it again.Examine Problems Closely: Instead of avoiding challenges, look for clues within the problem itself to guide solutions.Break Down the Problem: Address each component of the challenge one step at a time.Stay Focused: Resist the urge to pivot too quickly; often, solutions lie in persistence.Find Inspiration: Remember the impact your work can have on others to stay motivated.By following Dale's example and advice, you can make perseverance in problem-solving a skill. With practice and effort, you could make it a superpower that enables you to do more good in the world.Remember, however, that research into success suggests that building on your own superpowers is more important than creating new ones or overcoming weaknesses. You do you!Guest ProfileDale M. Walker (she/her):Co-founder, owner, and Chief Executive Officer, The Burlington HC Research Group, Inc. (BHCRG)About The Burlington HC Research Group, Inc. (BHCRG): BHCRG is working to advance a new family of investigational drugs called BRG Therapeutics. Based on pre-clinical studies, two members of this family show potent anticancer activity across human cancer cell lines representing seven different tissues of origin, including lung cancer (four subtypes), prostate cancer (three types), triple-negative breast cancer (two types), ovarian cancer (two types), pancreatic cancer (one type), pleural mesothelioma (two types), and pre-myeloblastic leukemia (one type, tested with a single BRG drug). In tissue-culture models, BRG drugs demonstrate an unusually strong ability to eliminate nearly all cancer cells after a single dose while achieving this result at doses that are non-toxic to normal human cells. Each BRG drug delivers two active ingredients, and the primary component (ingredient #1) also inhibits the replication of viruses spanning all three major viral genome classes—DNA viruses, RNA viruses, and reverse-transcribing/retroviruses—with activity shown in vitro against influenza, COVID-19, HIV, and Ebola and other viruses. Although such breadth is uncommon and has led some observers to believe no drug could achieve these effects, the evidence shows that the human body naturally produces several essential compounds with similarly broad anticancer and antiviral functions; BRG drugs work through analogous biochemical mechanisms but produce stronger effects in controlled laboratory studies. These naturally occurring comparators include N-acetylcysteine, glutathione, and vitamin C (only at pharmacologic doses). Taken together, BRG Therapeutics represents a next-generation, multi-targeted approach designed to overcome one of the central limitations of modern oncology—drug resistance—by restoring normal cellular regulation, reactivating p53, correcting redox imbalance, and neutralizing reactive species to selectively eliminate cancer cells while preserving healthy tissue.Website: bhcrg.comCompany Facebook Page: facebook.com/profile.php?id=61584197824692Other URL: invest.fundinghope.com/offering/brg/detailsBiographical Information: My husband Vernon and I work together as a team, and we have advanced BRG therapeutics to their present state of development by collaboration. We both are veterinarians with advanced training in pathology, so that make us ‘veterinary pathologists'. Vernon also has a PhD in experimental and molecular pathology. What many people do not know is that veterinary pathologists have key roles in drug development and safety testing. Before the discovery of the BRG drugs, most of our work focused on health risks from human exposures to environmental, workplace, or medicinal agents/compounds. We were working with BRG active ingredient #1, which is FDA-approved as the active form of a cell protective drug – that means that it protects normal cells from the damaging effects of radiation and some chemicals. We were testing the ability of this agent to protect normal cells from the deleterious effects of some of the first drugs like AZT developed to treat HIV. We were surprised to learn that this cell protective drug had antiviral activity all on its own. Even though this active ingredient had been around for several decades, no one had ever reported these results before we did. We soon learned why we were the first to make this discovery - the active ingredient of this cell protective drug worked well in tissue culture as an antiviral agent, but antiviral effects were not achieved in living animals. This sent us on a long road figuring out why this was – after all, this agent worked to protect normal cells in living animals and people, so why would it not work as an antiviral agent in the same animals and people? It actually took several years to understand the nature of the problems, and even more time to figure out a solution. That solution was the BRG therapeutics.Vernon and I had little experience studying viruses, and much more experience studying cancer and anticancer drugs, and we knew that this active ingredient had anticancer activity, so we decided to start with testing a BRG drug as an anticancer agent. Our first experiment in a human, pre-myeloblastic leukemia cell line showed us anticancer effects beyond anything that we could have imagined. We were so excited, but we still had a long journey of work and discovery ahead of us. To date we have tested two BRG drugs and they kill cancer cells in all human cancer cell lines tested to date (one drug tested in 15 human cancers, the other tested in 14). A paper summarizing these results was published in 2023.LinkedIn Profile: linkedin.com/in/dale-m-walker-bhcrgPersonal Facebook Profile: facebook.com/profile.php?id=61556212335476Support Our SponsorsOur generous sponsors make our work possible, serving impact investors, social entrepreneurs, community builders and diverse founders. Today's advertisers include FundingHope, and SuperGreen Live. Learn more about advertising with us here.Max-Impact Members(We're grateful for every one of these community champions who make this work possible.)Brian Christie, Brainsy | Cameron Neil, Lend For Good | Carol Fineagan, Independent Consultant | Hiten Sonpal, RISE Robotics | John Berlet, CORE Tax Deeds, LLC. | Justin Starbird, The Aebli Group | Lory Moore, Lory Moore Law | Mark Grimes, Networked Enterprise Development | Matthew Mead, Hempitecture | Michael Pratt, Qnetic | Mike Green, Envirosult | Dr. Nicole Paulk, Siren Biotechnology | Paul Lovejoy, Stakeholder Enterprise | Pearl Wright, Global Changemaker | Scott Thorpe, Philanthropist | Sharon Samjitsingh, Health Care Originals | Add Your Name HereUpcoming SuperCrowd Event CalendarIf a location is not noted, the events below are virtual.Superpowers for Good Live Pitch, December 11, 2025, at 8:00 PM Eastern / 5:00 PM Pacific, will bring together four mission-driven founders—Fran Maier (BabyQuip), Farooq Zama (CureValue), Andrei Evulet (Jetoptera), and Erin Martin (Pump For Joy)—as they present their companies live to a national audience on e360tv, YouTube, and LinkedIn. Hosted by Devin Thorpe, CEO and Founder of The Super Crowd, Inc., this special broadcast showcases entrepreneurs raising capital to solve real-world problems across family travel, healthcare access, disaster response aviation, and maternal health. Viewers are encouraged to watch the live pitches and then continue the experience by joining the Private Investor Session immediately following the broadcast, where attendees can engage directly with founders, ask deeper questions, and explore their active investment offerings in a focused, off-air environment. Whether you are an active investor or simply interested in the future of mission-driven innovation, this event offers a rare opportunity to witness purpose-driven companies in action and connect with them directly after the show.Impact Cherub Club Meeting hosted by The Super Crowd, Inc., a public benefit corporation, on December 16, 2025, at 1:30 PM Eastern. Each month, the Club meets to review new offerings for investment consideration and to conduct due diligence on previously screened deals. To join the Impact Cherub Club, become an Impact Member of the SuperCrowd.SuperCrowdHour, December 17, 2025, at 12:00 PM Eastern, will feature Devin Thorpe, CEO and Founder of The Super Crowd, Inc., leading a session on “Designing a Winning Marketing Strategy for Your Investment Offering.” Drawing on his deep experience in impact crowdfunding and investment storytelling, Devin will break down the essential elements of building a marketing strategy that attracts, engages, and converts potential investors. Participants will learn how to identify and reach the right audience, craft messages that build trust, and develop a promotional plan that supports sustained momentum throughout a raise. Whether you're preparing for your first regulated investment crowdfunding campaign or looking to strengthen an ongoing one, this SuperCrowdHour will provide the insights and practical frameworks you need to elevate your offering and boost investor participation.SuperGreen Live, January 22–24, 2026, livestreaming globally. Organized by Green2Gold and The Super Crowd, Inc., this three-day event will spotlight the intersection of impact crowdfunding, sustainable innovation, and climate solutions. Featuring expert-led panels, interactive workshops, and live pitch sessions, SuperGreen Live brings together entrepreneurs, investors, policymakers, and activists to explore how capital and climate action can work hand in hand. With global livestreaming, VIP networking opportunities, and exclusive content, this event will empower participants to turn bold ideas into real impact. Don't miss your chance to join tens of thousands of changemakers at the largest virtual sustainability event of the year.Community Event CalendarSuccessful Funding with Karl Dakin, Tuesdays at 10:00 AM ET - Click on Events.CfPA President-elect's Vision for 2026 with Brian Belley, December 17 at 2:00 PM ET – reserve your spot now!If you would like to submit an event for us to share with the 10,000+ changemakers, investors and entrepreneurs who are members of the SuperCrowd, click here.We use AI to help us write compelling recaps of each episode. Get full access to Superpowers for Good at www.superpowers4good.com/subscribe
Yogev Debbi and Prof Avi Schroeder (Technion Israel Institute of Technology), co-founded Mana bio along with Dr. Kira Radinsky and Roy Nevo. They are leveraging data, machine learning and high throughput screening to design novel Lipid NanoParticles for targeted extrahepatic delivery of nucleic acid therapeutics and vaccines. Lipid nanoparticles are microscopic fatty bubbles that deliver genetic medicines into your cells—think of them as the FedEx trucks of molecular biology. Remember the mRNA vaccines that saved millions during COVID? They used lipid nano particles as the delivery vehicle.. The little secret behind those vaccines is that we got lucky. Those lipid nanoparticles worked beautifully for the liver and immune system. But if you try to deliver RNA to your brain, your lungs, or a tumor, those would be a massive failure! Scientists are still running thousands of experiments hoping to stumble onto the right formulation. This actually was my postdoc work as well, which makes this episode very special. I always wished there was a better way to design these delivery vehicles—and that's exactly what today's guests have built with AI." We talk about how they founded and currently building Mana Bio- a big part around how biologists and chemists can interact with technologists, especially data and AI geeks to build something important. Their story provides a great framework for scientists and tech folks to work together. Shownotes: https://www.mana.bio/ How Avi got started using data/AI to design LNPs Optimizing LNP formulations targeting different organs Working with Bob Langer and Dan Anderson @MIT Yogev transitioning to gene editing Defining the problem & cross disciplinary conversations and projects Language that helps interactions between scientists and software/AI folks Deepdive into the platform- building data sets Data scraping, validation, improvisation, new data generation (both positive and negative data) Cleaning data and normalization Work in the wet lab: 'I trust my colleagues and believe data can be replicated" Data moats: Proprietary data vs public data Daily routine in the lab and interactions with the data/AI team Cross Functional dynamics Scientists trying to save money vs optimizing for more valuable time Lab hypothesis predictions vs AI predictions: competitive spirit Factoring in errors by the machines and humans Business model: Building customized solutions for drug delivery Potentially becoming a pharma company Regulatory affairs Fears that keep them up Dynamics of a diverse founding team: Roy Nevo and Dr. Kira Radinsky (the other two co founders) Message to academia: "Publish more data- including failures. This will accelerate science" Omri Drory, Kira Radinsky https://www.youtube.com/watch?v=y5hX3vq3iNk
In deze aflevering duiken we in de manier waarop de coronaperiode is verlopen, hoe RNA-technologie daarin een rol speelde en waarom de communicatie tussen wetenschap, media en politiek zo onder spanning kwam te staan. We verkennen wat deze dynamiek betekent voor vertrouwen, besluitvorming en de lessen die we kunnen trekken voor toekomstige crises. Wat zegt dit alles over het tijdperk waar we nu in zijn beland?--Maak het geluid van de Nieuwe Wereld volgend jaar ook mogelijk. Zonder uw steun geen DNW! Word lid of doneer:
Major health organizations, including the CDC and ACOG, recommend universal Hepatitis C Virus (HCV) screening for all pregnant women during each pregnancy and at time of delivery. Ideally, pregnant women should be screened for hepatitis C virus infection at the first prenatal visit of each pregnancy. If the antibody screen result is positive, hepatitis C virus RNA polymerase chain reaction testing is done to confirm the diagnosis. The risk of perinatal transmission of HCV is up to 9%, with at least one-third of transmissions occurring antenatally. While antiviral therapy is recommended for Hepatitis B in pregnancy with a viral load greater than 200,000 international units/mL to decrease the risk of vertical transmission, the same is not the case for Hep C. According to the ACOG CPG #6 from September 2023, there are no standard treatment protocols for Hep C in pregnancy but a new publication from the PINK journal (7 Dec 2025) is calling for a change. That new publication is, “Hepatitis C Treatment During Pregnancy: Time for a Practice Change”. Listen in for details. 1. ACOG CPG #6; Sept 20262. Bhattacharya D, Aronsohn A, Price J, Lo Re V. Hepatitis C Guidance 2023 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America. 2023;:ciad319. doi:10.1093/cid/ciad319.3. Chappell CA, Kiser JJ, Brooks KM, et al. Sofosbuvir/¬Velpatasvir Pharmacokinetics, Safety, and Efficacy in Pregnant People With Hepatitis C Virus. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 2025;80(4):744-751. doi:10.1093/cid/ciae595.4. Reau N, Munoz SJ, Schiano T. Liver Disease During Pregnancy. The American Journal of Gastroenterology. 2022;117(10S):44-52. doi:10.14309/ajg.0000000000001960.5. Dutra, Karley et al. Hepatitis C Treatment During Pregnancy: Time for a Practice Change. American Journal of Obstetrics & Gynecology MFM, Volume 0, Issue 0, 1018656. Society for Maternal-Fetal Medicine Consult Series #56: Hepatitis C in Pregnancy-Updated Guidelines: Replaces Consult Number 43, November 2017. Society for Maternal-Fetal Medicine (SMFM). Electronic address: pubs@smfm.org, Dotters-Katz SK, Kuller JA, Hughes BL. American Journal of Obstetrics and Gynecology. 2021;225(3):B8-B18. doi:10.1016/j.ajog.2021.06.008
Italia storica nel nuoto, agli Europei in vasca corta di Lublino, in Polonia: gli azzurri vincono per la prima volta di sempre il medagliere di questa manifestazione con un totale di 9 ori, 5 argenti e 6 bronzi.
Send us a textDr. Norman Putzki, MD is Senior Vice President, Global Clinical Development Head, and U.S. Development Site Head at Novartis ( https://www.novartis.com/ ) where he oversees global teams working on next-generation gene therapies, RNA-based medicines, targeted biologics, and innovative small molecules.Dr. Putzki most recently served as Global Head of Development for Neuroscience and Gene Therapy at Novartis, where he oversaw one of the world's most ambitious pipelines aimed at transforming the lives of patients with neurological, neuromuscular, and rare genetic diseases. A physician–scientist by training, with an MD from University of Duisburg Essen, Dr. Putzki has built a career at the intersection of clinical medicine, translational research, and large-scale drug development. Before joining Novartis, Dr. Putzki led programs across multiple therapeutic areas at Biogen Idec and has played key roles in advancing clinical treatments for conditions long considered intractable including MS and Parkison's disease.Beyond his scientific and clinical contributions, Dr. Putzki is widely recognized for his commitment to patient-centered innovation and his ability to bring together cutting-edge science, regulatory acumen, and real-world medical insight. Important Episode Links - Zolgensma Web Site - https://www.zolgensma.com/Itvisma Web Site - https://www.itvisma.com/Nature Medicine Papers For Itvisma Phase III study - Intrathecal onasemnogene abeparvovec in treatment-naive patients with spinal muscular atrophy: a phase 3, randomized controlled trial - https://www.nature.com/articles/s41591-025-04103-wIntrathecal onasemnogene abeparvovec for treatment-experienced patients with spinal muscular atrophy: a phase 3b, open-label trial - https://www.nature.com/articles/s41591-025-04119-2#NormanPutzki #Novartis #Neuroscience #GeneTherapy #SpinalMuscularAtrophy #SMN1 #SurvivalMotorNeuron1 #Zolgensma #OnasemnogeneAbeparvovec #AdenoAssociatedVirusSerotype9 #AAV9 #SMA #AveXis #Itvisma #NewbornScreening #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #ViralPodcast #STEM #Innovation #Technology #Science #ResearchSupport the show
It's The Ranch It Up Radio Show! Join Jeff Tigger Erhardt, Rebecca Wanner AKA BEC and their crew as they hear how feeding Farmatan to bred cows now can help prevent scours this upcoming calving season. Plus news, markets, updates, bred cow prices and lots more on this all-new episode of The Ranch It Up Radio Show. Be sure to subscribe on your favorite podcasting app or on the Ranch It Up Radio Show YouTube Channel. How To Prevent Calf Scours: Feed Farmatan Feed Farmatan To Prevent Scours This Upcoming Calving Season Calving season is getting ready to start for many producers and for some others it is still a ways away yet. Regardless, we need to get a jump on scours and make sure each and every calf that hits the ground has the best chance of survival. A simple solution… FARMATAN from Imogene Ingredients. WHAT CAUSES SCOURS IN BEEF CATTLE/CALVES Clostridia-Enterotoxemia The most common form of Clostridium in cattle is caused by Clostridia perfringens. The gram-positive bacteria are a challenge due to its ability to form spores and lay dormant for long-periods of time. The bacteria reproduce by releasing spores into its environment (soil, feed, manure). The spores can even lay dormant in the animal's intestine until opportunity presents itself. Infection takes place either through ingestion of spores or through an open wound. The most severe cases happen within the first month of a calf's life, and can result in sudden death. Clinical Signs Diarrhea - Bloody, Mucus Present, Bubbly Dehydrated Bloat Blindness Prevention/Treatment: Prevention can be difficult due to the Clostridia spores being extremely durable and present almost everywhere. Complete cleanout and disinfection between calves is helpful, but not always effective. A good vaccination program will reduce clinical disease. The best method is to develop good gut health and the immune system of the calf. Farmatan has been shown to strengthen the intestinal wall, helping to prevent infection from taking hold. Coccidiosis Cattle are host to numerous species of Coccidia, a single-celled protozoal parasite. Infection and clinical symptoms can happen any time during a calf's life, with the most severe reaction usually occurring between 3-6 weeks of age. The life-cycle of coccidia requires time to infect the intestine causing destruction of the mucosal and epithelial lining. The oocytes mature outside the host in warm, moist environments before being consumed, causing infection of a new host. Clinical Signs Diarrhea - Watery, Bloody Depression Weight Loss Prevention/Treatment: Prevention of Coccidiosis is possible by keeping young calves separate from older animals, providing clean water and feed, and dry conditions. Isolation of infected animals is key to preventing transmission. Keeping the pen dry is the most important step a farmer/rancher can take in preventing Coccidiosis. Treatment can have a good impact on reducing secondary disease, and speeding up recovery time. Farmatan has been shown to disrupt the reproductive cycle of Coccidia; and may help strengthen the intestinal wall to prevent infection, in both the cow and calf. Coronavirus Bovine Coronavirus is a ubiquitous, envelope-viral disease, causing respiratory and enteric infection. There are many serotypes for this virus, making it difficult to test for, and create a vaccine. Coronavirus can present as either diarrhea and/or respiratory illness; transmitted through nasal discharge and/or feces. Animal reservoirs continue to spread the disease, and make eradication almost impossible. Clinical disease will likely occur between days 10-14, and present for up to 4 days. Clinical Signs Diarrhea - Watery Nasal Discharge Coughing Prevention/Treatment: Prevention is difficult due to wild animals transmitting the disease. Keeping wild animals out of animal enclosures is essential. Isolation of infected animals is critical to preventing the spread of Coronavirus. Adequate colostrum intake, along with a good vaccination program will help prevent clinical disease. Learn more about the positive effects of Farmtan's active ingredient on Coronavirus HERE. Cryptosporidium Cryptosporidium Parvum is a single-celled parasite responsible for causing infection in young calves. The infection takes place within the first four weeks of a calves' life, afterwards immunity has developed within the calf. The parasite is either passed from the cow or spread through infected water sources. Clinical Signs Diarrhea - Watery, Bloody, Mucus present Colic Depression Prevention/Treatment: Good sanitary conditions, especially clean water is essential in preventing transmission of cryptosporidium. Isolation of sick calves will help reduce the effect on the overall herd. There is some good effect of calves given adequate colostrum, however this is likely helping by reducing other pathogenic loads rather than a direct effect on Cryptosporidium, itself. Farmatan fed prior to calving has been shown to disrupt the life-cycle and reduce transmission from the cow. The direct action of Farmatan on the parasite makes it an excellent choice for treating calves. Learn more about the positive effect of Farmatan's active ingredient HERE. E-Coli Escherichia Coli is a bacterial infection that affects calves within the first week of their life. The bacteria colonize in the lower intestine and produce a toxin. The toxin causes excessive secretion of fluids. The zoonotic disease has special importance in food safety and human health. Colostrum and natural immunity are often not sufficient in preventing infection in cases of high bacterial concentrations. Clinical Signs Diarrhea - Creamy, Yellow Abdominal Pains Fever Vomiting Prevention/Treatment: The best prevention methods for E. Coli include: clean water, dry bedding/environment, isolation of infected animals, and vaccination. Treatment with antibiotics and oral fluids have great benefits in reducing clinical symptoms of the disease. Farmatan has been shown to reduce bacterial load and help prevent infection. Learn more about the positive effects of Farmatan's active ingredient HERE. Rotavirus Rotavirus in calves is caused by a virus belonging to the Reoviridae family, as a non-envelope RNA virus. Rotavirus is thought to be the most common cause of neonatal diarrhea in calves. The virus tends to affect calves between the age of 1-day-old up to a month, with most cases presenting within the first week of life. Shedding and reinfection can happen in older calves and cows. Clinical symptoms are rarely present after the first month of life; older animals tend to either be carriers or asymptomatic. The majority of herds have some level present, with transmission likely happening during or shortly after birth. Clinical Signs Diarrhea - Pale Yellow, Bloody Dehydrated Dull calves Reluctant to drink Prevention/Treatment: The ideal scenario is to prevent infection through, sanitary facilities (calving barn), outdoor calf housing, and a good vaccination program. Colostrum will provide much needed antibodies, protecting the calf before their immune system is fully developed to combat the disease. Farmatan fed prior to calving can help reduce the pathogen load of the cow, reducing the likelihood of transmission. Farmatan supplemented in the milk has been shown to decrease the virus' ability to cause infection and clinical disease. The best treatment for calves already presenting clinical disease is to administer oral fluids/electrolytes to rehydrate the calf. Learn more about the positive effect of Farmatan's active ingredient HERE. Salmonella Salmonella infection of cattle is caused by a variety of species within the family. While the disease is uncommon in cattle with little effect on calf health, it has massive implications for human health and food safety. The bacteria spreads through direct contact or contaminated feed & water. This disease is highly regulated by the USDA. The most severe cases of salmonella affect calves between the ages of 7-10 days old. Clinical Signs Diarrhea - Bloody (flakes of slough tissue), Watery, Mucus present Lethargic Fever Prevention/Treatment: Prevention is always the best option: provide clean water, feed, and bedding. Isolate infected animals, ensure adequate colostrum intake, and develop a vaccination program with your veterinarian. Treatment with antibiotics and fluids (oral or intravenous) greatly increases the survival rate of calves infected with Salmonella. Farmatan has been shown to help reduce the likelihood of infection by protecting the gut, and reduce recovery time of infected animals. LEARN MORE ABOUT IMOGENE INGREDIENTS PRODUCTS Paul Mitchell & Paul Martin on RFD TV Rural America Live! WATCH: https://vimeo.com/759549430/bd063fcc1f Beef Industry News Possible Slow Beef Trend in 2026 According To Rabobank Beef production by major global producers is expected to remain sluggish next year, according to analysts at the Dutch financial services cooperative Rabobank. The recent contraction in beef production is expected to affect major producers in Brazil, Canada and the United States, with New Zealand being likely to see the sharpest percentage drop in beef production, the Rabobank report predicted. Several issues are contributing to the 2025 decline and the expected drop next year, especially in light of limited cattle herds ready for slaughter in both the United States and Brazil, the report added. The long-term contraction of available cattle is being blamed for significant price hikes for retail beef in the last few years, Rabobank noted. Canada is experiencing a tighter pattern that has resulted in a decline of 41,000 metric tons of beef available for export in 2025 versus levels in 2024, according to the report. Canadian beef output in 2026 is expected to be “more limited” compared with this year for reasons also being experienced south of the Canadian border in terms of the available cattle herd. References: https://meatingplace.com/slower-beef-production-trend-to-continue-in-2026-rabobank/?utm_source=omeda&utm_medium=email&utm_cid=1103020073&utm_campaign=MTGMCD251201004&utm_date=20251201-1300 New World Screwworm Website Tracks Parasite There's a new way for producers and other stakeholders to track the fight against the New World Screwworm — a parasite that threatens live cattle herds. The USDA has launched a dedicated website with up-to-date information on the spread of the screwworm, which so far has been confined to cattle in several Mexican states near the U.S. border. The site includes resources for livestock producers, veterinarians, animal-health officials, wildlife experts, healthcare providers, pet owners, researchers, drug manufacturers, and the general public. Reports of the pest in Mexican cattle prompted the U.S. to halt cattle imports from Mexico back in May. USDA also committed $21 million to boost sterile fly production in Mexico as part of its response. The new website pulls together information from multiple federal partners, including the FDA, the Department of Energy, Homeland Security, the EPA, and the State Department. Reference: https://www.aphis.usda.gov/livestock-poultry-disease/stop-screwworm Nightshade In Corn Residue Could Be Toxic Have you noticed any black nightshade in your corn stalks that you are grazing or plan to graze? If these fields have too much black nightshade, be careful — it might be toxic. Black nightshade is common in many corn fields in the fall, especially those that had hail damage in the summer or any situation where the corn canopy became thin or open. It usually isn't a problem, but if the density of nightshade is very high, there is the potential that it could poison livestock. Almost all livestock, including cattle, sheep, swine, horses and poultry are susceptible. Black nightshade plants average about two feet in height and have simple alternating leaves. In the fall, berries are green and become black as the plant matures. All plant parts contain some of the toxin and the concentration increases as plants mature, except in the berries. Freezing temperatures will not reduce the toxicity. It is very difficult to determine exactly how much black nightshade is risky. Guidelines say that a cow would need to consume three to four pounds of fresh black nightshade to be at risk of being poisoned. These guidelines, though, are considered conservative since there is little data on the actual toxicity of nightshade plants. Fortunately, even though nightshade plants remain green fairly late into the fall, cattle usually don't appear to seek out nightshade plants to graze. However, green plants of nightshade might become tempting toward the end of a field's grazing period when there is less grain, husks or leaves to consume. References: https://www.nationalbeefwire.com/nightshade-in-corn-residue-grazing-could-be-toxic Featured Experts in the Cattle Industry Paul Mitchell – Imogene Ingredients https://www.imogeneingredients.com/ Follow on Facebook: @FarmatanUSA Kirk Donsbach – Financial Analyst at StoneX https://www.stonex.com/ Follow on Facebook: @StoneXGroupInc Shaye Wanner – Host of Casual Cattle Conversation https://www.casualcattleconversations.com/ Follow on Facebook: @cattleconvos Contact Us with Questions or Concerns Have questions or feedback? Feel free to reach out via: Call/Text: 707-RANCH20 or 707-726-2420 Email: RanchItUpShow@gmail.com Follow us: Facebook/Instagram: @RanchItUpShow YouTube: Subscribe to Ranch It Up Channel: https://www.youtube.com/c/RanchItUp Catch all episodes of the Ranch It Up Podcast available on all major podcasting platforms. Discover the Heart of Rural America with Tigger & BEC Ranching, farming, and the Western lifestyle are at the heart of everything we do. Tigger & BEC bring you exclusive insights from the world of working ranches, cattle farming, and sustainable beef production. Learn more about Jeff 'Tigger' Erhardt & Rebecca Wanner (BEC) and their mission to promote the Western way of life at Tigger and BEC. https://tiggerandbec.com/ Industry References, Partners and Resources For additional information on industry trends, products, and services, check out these trusted resources: Allied Genetic Resources: https://alliedgeneticresources.com/ American Gelbvieh Association: https://gelbvieh.org/ Axiota Animal Health: https://axiota.com/multimin-campaign-landing-page/ Imogene Ingredients: https://www.imogeneingredients.com/ Jorgensen Land & Cattle: https://jorgensenfarms.com/#/?ranchchannel=view Medora Boot: https://medoraboot.com/ RFD-TV: https://www.rfdtv.com/ Rural Radio Network: https://www.ruralradio147.com/ Superior Livestock Auctions: https://superiorlivestock.com/ Transova Genetics: https://transova.com/ Westway Feed Products: https://westwayfeed.com/ Wrangler: https://www.wrangler.com/ Wulf Cattle: https://www.wulfcattle.com/
The origin of life is one of the biggest challenges to secular scientists. Hear a leading expert expound upon a myriad of reasons why! There will be some work for these two. He shared his screen and showed some videos, but he sent me links to use that should be better (i.e., cut-out the live version and insert the video taken from the links he's giving us. See below my signature for those links).Also, his mic went out a number of times and he had to fix it quickly. That should all be edited out. Let me know if you have any questions.1) from Verisasium YouTube Channel, "The most controversial idea in biology":https://youtube.com/clip/UgkxDPCtBoV57kP7N3sy9BoBwKzaWOpKqk_c?si=iXXH4u0s19BVFOWo2) From Long Story Short, "Debunking popular science videos on the origin of life and RNA world"https://youtu.be/dKoWpWGS-zY?si=Ls8R0L6auKsASnFF from 4:28.6 to 4:50.93) From Long Story Short, "Surviving the Daily DNA Apocalypse"https://youtube.com/clip/UgkxmsQ_bxpMaYtHqtjeDsrkkqEONYRNG5Yo?si=wg3LPhwxdR8qUPGz4) From Long Story Short, "Surviving the Daily DNA Apocalypse"https://youtube.com/clip/UgkxrdEiIUifweDIR99ro_Z0Oe_P7D5N-UqE?si=io7tIULpVwLXQVC25) From Long Story Short, "Awkward truths about the origin of life: Energy and metabolism"https://youtube.com/clip/UgkxDfnmez63NDacsa2jp0S4o_QDdobuo8t1?si=y5R36fqCcVuLH8qU6) From Long Story Short, "Awkward truths about the origin of life: Energy and metabolism"https://youtube.com/clip/UgkxhE4pJPHFRDfkkGSlG_qTuYKulzGRxr59?si=9z5X5r9wDMWazKwM
Maria Barna is an authority on ribosomes – “life's most ancient and spectacular molecular machines.” Ribosomes make proteins in the body. There can be a thousand different types of ribosomes in a single cell, she says, each with a specific job to do. But sometimes things go awry and ribosomes get “hijacked,” leading to disease. Barna studies these “diabolical” variations to find new therapies to treat diseases ranging from cancer and COVID to Parkinson's. When diseases hit, it's all about the ribosomes, Barna tells host Russ Altman on this episode of Stanford Engineering's The Future of Everything podcast.Have a question for Russ? Send it our way in writing or via voice memo, and it might be featured on an upcoming episode. Please introduce yourself, let us know where you're listening from, and share your question. You can send questions to thefutureofeverything@stanford.edu.Episode Reference Links:Stanford Profile: Maria BarnaConnect With Us:Episode Transcripts >>> The Future of Everything WebsiteConnect with Russ >>> Threads / Bluesky / MastodonConnect with School of Engineering >>> Twitter/X / Instagram / LinkedIn / FacebookChapters:(00:00:00) IntroductionRuss Altman introduces guest Maria Barna, a professor of genetics at Stanford University.(00:04:21) Origins of Ribosome ResearchMaria explains why ribosomes became the focus of her work.(00:06:14) Ribosome Function and ScaleRibosomes' functions and the energy required for their production.(00:08:28) Ribosomes as MachinesHow ribosomes influence which proteins are produced and when.(00:09:48) Ribosome RegulationThe regulatory layers within ribosomes and their possible variants.(00:14:35) Ribosomes and DiseaseHow ribosomal dysfunction is linked to a wide range of diseases.(00:18:16) Ribosome Mutations and DevelopmentCongenital disorders that can be attributed to specific ribosomal mutations.(00:20:44) RNA vs. Protein OutputWhy RNA measurements alone do not accurately predict protein levels.(00:24:16) Designing Ribosomes for TherapyThe potential of using engineered ribosomes for target therapies.(00:26:16) Small-Molecule Ribosome ModulatorsScreening compounds that may enhance ribosome activity for treatments.(00:28:39) Future Ribosome ProfilingIsolating individual ribosomes to understand their specific roles.(00:30:35) Future In a MinuteRapid-fire Q&A: scientific progress, community, and alternative career interest.(00:34:01) Conclusion Connect With Us:Episode Transcripts >>> The Future of Everything WebsiteConnect with Russ >>> Threads / Bluesky / MastodonConnect with School of Engineering >>>Twitter/X / Instagram / LinkedIn / Facebook Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Click Here,Text Us,Get a Shout-Out next episode.This Episode recorded and rendered on Reaper DAW.Hit play on a cozy, candid ride through creative tinkering, 80s nostalgia, and the kind of gratitude that only grows after a hard season. We start in the studio where we stress-test a new workflow, recording in Reaper and Audacity at the same time to chase better sound without risking the show. That practical look at tools and trade-offs opens into a broader conversation about making independent media in a value-for-value world—keeping the feed free, leaning on community, and learning in public.From there we move to the table—Thanksgiving memories, a second quiet dinner at home, and a cat that insists on a cameo. Music threads it all together. We found WSQK, a Stranger Things–themed internet radio station that spins 80s tracks and sly story nods, and it turned into an all-day soundtrack. The nostalgia isn't just fun; it's a mood shaper. That sets up a timely dive into why singing helps your health, pulling from BBC reporting on reduced stress, steadier heart rate, group bonding, and the simple joy of joining in rather than just listening.We also chew on a science headline: the oldest sequenced RNA from a woolly mammoth calf frozen in Siberian permafrost. It's a fascinating claim that deserves both curiosity and caution, so we unpack what RNA can reveal, what speculation might overreach, and how to love science without surrendering our questions. The emotional center lands in a personal story of recovery after a 2019 stroke—losing speech, movement, everyday skills—and the slow return of strength through prayer, rehab, family, and time. Gratitude shifts from a holiday word to a lived practice, and that's the heartbeat carrying us forward.Want to be part of the flock? Share a thought, send a voicemail, or drop us a line. If this conversation moved you, follow, share with a friend, and leave a review so others can find the show. Your support—prayers, talent, or a few dollars—keeps the mics on and the stories coming.Support the show I hope you enjoy the show! We believe in Value4Value for the podcaster and the listener alike. If you find value in our show, Please tell a friend or two. Word of mouth is the best way for our podcast to grow. If you haven't already, hit the "Follow" button. If you feel lead to, click on the support link and give financially. Say a prayer for us. Most importantly, please come back!Supporting us in anyway is much appreciated.Thanks for stopping by. Until Next time.73 and may the Father's love go with you.Bruce Email: theuglyquackingduck@gmail.comInstagram: https://www.instagram.com/theuglyquackingduck TikTok: https://www.tiktok.com/@theuglyquackingduck Facebook: The Ugly Quacking Duck Podcast Website: https://theuglyquackingduck.com
Click Here,Text Us,Get a Shout-Out next episode.This Episode recorded and rendered on Reaper DAW.Hit play on a cozy, candid ride through creative tinkering, 80s nostalgia, and the kind of gratitude that only grows after a hard season. We start in the studio where we stress-test a new workflow, recording in Reaper and Audacity at the same time to chase better sound without risking the show. That practical look at tools and trade-offs opens into a broader conversation about making independent media in a value-for-value world—keeping the feed free, leaning on community, and learning in public.From there we move to the table—Thanksgiving memories, a second quiet dinner at home, and a cat that insists on a cameo. Music threads it all together. We found WSQK, a Stranger Things–themed internet radio station that spins 80s tracks and sly story nods, and it turned into an all-day soundtrack. The nostalgia isn't just fun; it's a mood shaper. That sets up a timely dive into why singing helps your health, pulling from BBC reporting on reduced stress, steadier heart rate, group bonding, and the simple joy of joining in rather than just listening.We also chew on a science headline: the oldest sequenced RNA from a woolly mammoth calf frozen in Siberian permafrost. It's a fascinating claim that deserves both curiosity and caution, so we unpack what RNA can reveal, what speculation might overreach, and how to love science without surrendering our questions. The emotional center lands in a personal story of recovery after a 2019 stroke—losing speech, movement, everyday skills—and the slow return of strength through prayer, rehab, family, and time. Gratitude shifts from a holiday word to a lived practice, and that's the heartbeat carrying us forward.Want to be part of the flock? Share a thought, send a voicemail, or drop us a line. If this conversation moved you, follow, share with a friend, and leave a review so others can find the show. Your support—prayers, talent, or a few dollars—keeps the mics on and the stories coming.Support the show I hope you enjoy the show! We believe in Value4Value for the podcaster and the listener alike. If you find value in our show, Please tell a friend or two. Word of mouth is the best way for our podcast to grow. If you haven't already, hit the "Follow" button. If you feel lead to, click on the support link and give financially. Say a prayer for us. Most importantly, please come back!Supporting us in anyway is much appreciated.Thanks for stopping by. Until Next time.73 and may the Father's love go with you.Bruce Email: theuglyquackingduck@gmail.comInstagram: https://www.instagram.com/theuglyquackingduck TikTok: https://www.tiktok.com/@theuglyquackingduck Facebook: The Ugly Quacking Duck Podcast Website: https://theuglyquackingduck.com
Juliet Cruz and Maria Nikokavoura from the University of Ottawa interview Dr. Giovanni Ferrari for the TMM4950 Science Communication course about pushing the limits of donor heart preservation times. Dr. Ferrari is an associate professor of surgical sciences and the Scientific director of the cardiothoracic research program at Columbia University. Dr. Ferrari's research focuses on exploring how the heart functions and how we can better protect it, especially during surgery and organ transplantation. In this episode, Dr. Ferrari presents his findings from their work on a revolutionary method to keep donor hearts viable for up to 48 hours outside the body using a novel oxygen-rich cooling system. This could dramatically expand access to life-saving transplants and reshape how we think about organ preservation.Learn more: https://columbiasurgery.org/about/giovanni-ferrari-phd 0:00 | Introduction to podcast0:18 | Introduction to Dr. Ferrari1:11 | What sparked Dr. Ferrari's early interest in the heart and organ preservation?2:59 | What is the HOPE system, and how does it differ from standard cold storage?5:32 | Why push the limits of donor heart preservation, and what challenges came with it?6:44 | What surprising insights emerged from the RNA and metabolomic analyses?9:15 | How did it feel to see a HOPE-preserved heart beat again after 48 hours?11:15 | Can HOPE principles be applied to preserve other organs in transplantation?12:09 | What future research questions is the team most excited to pursue?14:30 | What advice does Dr. Ferrari have for young scientists bridging engineering and medicine?15:27 | Closing remarks“Only You with the Universe” by Spøq, licensed via Tribe of Noise PRO. All rights reserved. Listen more:https://prosearch.tribeofnoise.com/artists/show/78252/44118 Juliet Cruz and Maria Nikokavoura (Voice), Reena Corbane (Post-Production), Nika Abedian (Producer)
Alejandro Sánchez Alvarado, Ph.D., argues that real progress in understanding regeneration comes from studying whole organisms rather than cells grown under artificial conditions. Sánchez Alvarado shows how observations from intact animals reveal organizing rules that narrow laboratory systems can miss. He presents evidence that stem cells in a studied animal lack detectable junctions with neighboring cells and instead respond to signals that travel across tissues. Sánchez Alvarado links this communication to extracellular vesicles that carry RNA and to metabolic support involving creatine, highlighting how distant tissues influence repair. Using imaging and molecular analyses, he tracks how signals move through the body and how specific cell populations change state during recovery. Sánchez Alvarado concludes that broad, comparative research is essential for uncovering general principles that govern how adult tissues restore form and function. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40454]
Alejandro Sánchez Alvarado, Ph.D., argues that real progress in understanding regeneration comes from studying whole organisms rather than cells grown under artificial conditions. Sánchez Alvarado shows how observations from intact animals reveal organizing rules that narrow laboratory systems can miss. He presents evidence that stem cells in a studied animal lack detectable junctions with neighboring cells and instead respond to signals that travel across tissues. Sánchez Alvarado links this communication to extracellular vesicles that carry RNA and to metabolic support involving creatine, highlighting how distant tissues influence repair. Using imaging and molecular analyses, he tracks how signals move through the body and how specific cell populations change state during recovery. Sánchez Alvarado concludes that broad, comparative research is essential for uncovering general principles that govern how adult tissues restore form and function. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40454]
Alejandro Sánchez Alvarado, Ph.D., argues that real progress in understanding regeneration comes from studying whole organisms rather than cells grown under artificial conditions. Sánchez Alvarado shows how observations from intact animals reveal organizing rules that narrow laboratory systems can miss. He presents evidence that stem cells in a studied animal lack detectable junctions with neighboring cells and instead respond to signals that travel across tissues. Sánchez Alvarado links this communication to extracellular vesicles that carry RNA and to metabolic support involving creatine, highlighting how distant tissues influence repair. Using imaging and molecular analyses, he tracks how signals move through the body and how specific cell populations change state during recovery. Sánchez Alvarado concludes that broad, comparative research is essential for uncovering general principles that govern how adult tissues restore form and function. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40454]
Alejandro Sánchez Alvarado, Ph.D., argues that real progress in understanding regeneration comes from studying whole organisms rather than cells grown under artificial conditions. Sánchez Alvarado shows how observations from intact animals reveal organizing rules that narrow laboratory systems can miss. He presents evidence that stem cells in a studied animal lack detectable junctions with neighboring cells and instead respond to signals that travel across tissues. Sánchez Alvarado links this communication to extracellular vesicles that carry RNA and to metabolic support involving creatine, highlighting how distant tissues influence repair. Using imaging and molecular analyses, he tracks how signals move through the body and how specific cell populations change state during recovery. Sánchez Alvarado concludes that broad, comparative research is essential for uncovering general principles that govern how adult tissues restore form and function. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40454]
Alejandro Sánchez Alvarado, Ph.D., argues that real progress in understanding regeneration comes from studying whole organisms rather than cells grown under artificial conditions. Sánchez Alvarado shows how observations from intact animals reveal organizing rules that narrow laboratory systems can miss. He presents evidence that stem cells in a studied animal lack detectable junctions with neighboring cells and instead respond to signals that travel across tissues. Sánchez Alvarado links this communication to extracellular vesicles that carry RNA and to metabolic support involving creatine, highlighting how distant tissues influence repair. Using imaging and molecular analyses, he tracks how signals move through the body and how specific cell populations change state during recovery. Sánchez Alvarado concludes that broad, comparative research is essential for uncovering general principles that govern how adult tissues restore form and function. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40454]
Alejandro Sánchez Alvarado, Ph.D., argues that real progress in understanding regeneration comes from studying whole organisms rather than cells grown under artificial conditions. Sánchez Alvarado shows how observations from intact animals reveal organizing rules that narrow laboratory systems can miss. He presents evidence that stem cells in a studied animal lack detectable junctions with neighboring cells and instead respond to signals that travel across tissues. Sánchez Alvarado links this communication to extracellular vesicles that carry RNA and to metabolic support involving creatine, highlighting how distant tissues influence repair. Using imaging and molecular analyses, he tracks how signals move through the body and how specific cell populations change state during recovery. Sánchez Alvarado concludes that broad, comparative research is essential for uncovering general principles that govern how adult tissues restore form and function. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40454]
Jim Foote, Co-Founder and CEO of First Ascent Biomedical, is changing the standard of care for cancer treatment from 'try and hope' to 'test and treat'. The First Ascent platform combines functional drug testing of fresh biopsies, genomic sequencing, and an AI engine to assess a large panel of drugs and identify the most likely to be effective. Clinical data show a high correlation between how cancer cells respond in the lab test and how patients respond to the same drug, and is seen as a treatment guide for refractory cancer patients to identify novel drug combinations. Jim explains, "Fundamentally speaking, if we look at everybody on this planet from a DNA and RNA perspective, there are 8 billion people, and each one of us is different from the others due to our DNA and RNA. So if we acknowledge that biologically we're all different, then the problem that we're trying to solve is if we're all different, why are we treating each patient with the same standard of care? A process that has existed for a hundred years, and again, they've made substantial advancements, but functional precision medicine is really an opportunity to move away from a standard that's based on the laws of averages and really treat people based on an individual level, developed by results that come from their individual biology." "In oncology, these practices and standards have been developed over decades. And in some situations, some of these cancer protocols haven't been updated in decades. There had been continual advancements in things like immunotherapy. What I'll say is that in oncology, they're always looking for the silver bullet. It's in the genome, it's in a biomarker, it's in immuno-oncology, it's in an organoid, it's in all of those types of things. So they have always tried to find that silver bullet. Fundamentally, what we do in First Ascent is that we believe that we have enough bullets, per se. We have enough drugs, per se. We're just not using them in the right ways. " #FirstAscentBiomedical #Cancer #Oncology firstascentbiomedical.com Download the transcript here
Jim Foote, Co-Founder and CEO of First Ascent Biomedical, is changing the standard of care for cancer treatment from 'try and hope' to 'test and treat'. The First Ascent platform combines functional drug testing of fresh biopsies, genomic sequencing, and an AI engine to assess a large panel of drugs and identify the most likely to be effective. Clinical data show a high correlation between how cancer cells respond in the lab test and how patients respond to the same drug, and is seen as a treatment guide for refractory cancer patients to identify novel drug combinations. Jim explains, "Fundamentally speaking, if we look at everybody on this planet from a DNA and RNA perspective, there are 8 billion people, and each one of us is different from the others due to our DNA and RNA. So if we acknowledge that biologically we're all different, then the problem that we're trying to solve is if we're all different, why are we treating each patient with the same standard of care? A process that has existed for a hundred years, and again, they've made substantial advancements, but functional precision medicine is really an opportunity to move away from a standard that's based on the laws of averages and really treat people based on an individual level, developed by results that come from their individual biology." "In oncology, these practices and standards have been developed over decades. And in some situations, some of these cancer protocols haven't been updated in decades. There had been continual advancements in things like immunotherapy. What I'll say is that in oncology, they're always looking for the silver bullet. It's in the genome, it's in a biomarker, it's in immuno-oncology, it's in an organoid, it's in all of those types of things. So they have always tried to find that silver bullet. Fundamentally, what we do in First Ascent is that we believe that we have enough bullets, per se. We have enough drugs, per se. We're just not using them in the right ways. " #FirstAscentBiomedical #Cancer #Oncology firstascentbiomedical.com Listen to the podcast here
In this highly insightful episode of The Future Conceived, host Cam Schmidt talks with Dr. Carmen Williams, Senior Investigator at the National Institute of Environmental Health Sciences and the 2025 winner of the SSR Research Award.Dr. Williams, whose lab investigates the critical events of fertilization, shares groundbreaking findings on calcium signaling during egg activation. You will learn:Why the simple components of in vitro culture media, specifically calcium and magnesium ratios, dramatically control the frequency of calcium oscillations and influence the quality and development of the resulting embryo.New, compelling evidence linking these early calcium signals to metabolism (TCA cycle) and ribosomal RNA synthesis in the early embryo.The continued importance of research into endocrine disruptors, particularly plant estrogens, and their impact on reproductive tract differentiation.Dr. Williams also discusses her journey from electrical engineering to clinical medicine to basic science, and closes with a powerful message acknowledging the essential role of trainees in driving scientific success.
Welcome back to the Information Entropy Podcast! In this episode, we break down the building blocks of life, from atoms and molecules to DNA and RNA. We then dive into the world of genetic engineering, exploring what CRISPR is, how it works, and why it's become one of the most important tools in modern biology and why scientists are so eager to rewrite genetic code. This week is Part 1 where we set the stage and foundational knowledge, next week we will explore the possible exploitations of such a technology… good and bad! Music: HOME – AWAY
You don't have to understand every medical term to receive a miracle. In this powerful healing prayer session, Kathy leads you to target DNA, RNA, proteins, and prions so you can contend for full manifestation of your healing in Christ. Purchase Kathy's book Healed at Last – Overcome Sickness to Receive your Physical Healing on Amazon https://a.co/d/6a6mt8w or at: https://www.kathydegrawministries.org/healed-at-last/ Purchase Anointing Oil with a prayer cloth that Kathy has personally mixed and prayed over on Kathy's Website or Amazon. Order anointing oil by Kathy on Amazon look for her brand here https://amzn.to/3PC6l3R or Kathy DeGraw Ministries https://www.kathydegrawministries.org/product-category/oils/ Training, Mentorship and Deliverance! Personal coaching, deliverance, ecourses, training for ministry, and mentorships! https://www.kathydegrawministries.org/training/# In this prophetic healing and deliverance message, Kathy DeGraw equips you to pray at a deeper, more specific level over your body for radical breakthrough. Instead of just saying "rash go" or "sickness leave," you will learn to command every cell, chromosome, and protein to align with the perfect DNA and RNA God designed before the foundation of the world. Kathy releases targeted declarations over 125 trillion cells, T-cells, prions, the nervous system, immune system, gastrointestinal system, and especially neurodegenerative disorders such as dementia, Parkinson's, Alzheimer's, ADHD, and brain damage from trauma or birth defects. As you stand in the gap for yourself and your loved ones, you will renounce generational curses, break familiar spirits, and decree divine regeneration over your bloodline. If you are hungry to see what medical science says is impossible bow to the name of Jesus, this episode will train you how to pray, decree, and receive supernatural healing at the cellular level. #healingprayer #DNAhealing #neurologicalhealing #cellularrestoration #propheticspiritualwarfare **Connect with Us** - Website: https://www.kathydegrawministries.org/ - Facebook: https://www.facebook.com/kathydegraw/ - Instagram: https://www.instagram.com/kathydegraw/ Podcast - Subscribe to our YouTube channel and listen to Kathy's Podcast called Prophetic Spiritual Warfare, or on Spotify at https://open.spotify.com/show/3mYPPkP28xqcTzdeoucJZu or Apple podcasts at https://podcasts.apple.com/us/podcast/prophetic-spiritual-warfare/id1474710499 **Recommended Resources:** - Receive a free prayer pdf on Warfare Prayer Declarations at https://kathydegrawministries.org/declarations-download - Kathy's training, mentoring and ecourses on Spiritual Warfare, Deliverance and the Prophetic: https://training.kathydegrawministries.org/ - Healed At Last ~ Overcome Sickness and Receive your Physical Healing: https://www.kathydegrawministries.org/healed-at-last/ - Mind Battles – Root Out Mental Triggers to Release Peace!: https://www.kathydegrawministries.org/product/mind-battles-pre-order-available-january-2023/ -Kathy has several books available on Amazon or kathydegrawministries.org **Support Kathy DeGraw Ministries:** - Give a one-time love offering or consider partnering with us for $15, $35, $75 or any amount! Every dollar helps us help others! - Website: https://www.kathydegrawministries.org/donate/ - CashApp $KDMGLORY - Venmo @KD-Ministries - Paypal.me/KDeGrawMinistries or donate to email admin@degrawministries.org - Mail a check to: Kathy DeGraw Ministries ~ PO Box 65 ~ Grandville MI 49468
Send us a textGood morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into the intricate tapestry of scientific advancements, regulatory decisions, and strategic maneuvers shaping our industry.One of the notable stories involves Agios Pharmaceuticals, which is pushing forward with its sickle cell disease treatment, Pyrukynd, for FDA approval. This comes despite mixed results from their Phase 3 clinical trials, which led to a significant drop in their stock value. This scenario underscores the complexities of navigating clinical trial outcomes while pursuing breakthroughs in treating challenging diseases like sickle cell.Arrowhead Pharmaceuticals has marked a significant milestone with the FDA's approval of Plozasiran. This achievement not only marks Arrowhead's entry into the commercial sector but also highlights the competitive dynamics within biotech, as companies like Ionis Pharmaceuticals vie for market dominance with innovative therapies. Further strengthening its position, Arrowhead also received FDA approval for Redemplo, a siRNA-based therapeutic for rare genetic metabolic disorders. Despite facing volatility due to safety concerns in its partnership with Sarepta Therapeutics, this approval underscores RNA interference therapies' potential in precision medicine.In corporate strategy news, Alkermes is making moves to acquire Avadel Pharmaceuticals, offering up to $2.37 billion and overshadowing a competing bid from Lundbeck. Such acquisitions are part of a broader trend of consolidation in the industry aimed at expanding portfolios and market reach. Avadel's decision to accept Alkermes' revised offer over Lundbeck's bid highlights ongoing consolidation trends as companies expand their portfolios in competitive markets like narcolepsy drugs.On the investment front, Celltrion has committed $478 million to upgrade a U.S. manufacturing facility acquired from Eli Lilly. This expansion is crucial for increasing manufacturing capabilities within the biosimilars sector, where demand for cost-effective therapeutics is on the rise. Additionally, Celltrion's exploration beyond biosimilars with a potential $350 million deal involving Trioar's antibody platform demonstrates ambition to diversify its portfolio towards innovative biologics.Teva Pharmaceuticals is fostering innovation by inviting startups to tackle key challenges within biopharma through a global platform. This initiative reflects a growing trend toward open innovation and collaboration, seeking novel solutions to complex issues across research and development and manufacturing efficiencies.In regulatory news, the controversial $7.4 billion settlement plan involving the Sackler family and Purdue Pharma has received approval from a bankruptcy judge. This paves the way for Purdue's transformation into Knoa Pharma and highlights ongoing legal and ethical reckonings related to opioid liabilities within the industry.Cytokinetics remains committed to its independent path as it awaits FDA approval for its cardiovascular drug Aficamtem. The company's determination to commercialize without big pharma support reflects a trend where smaller biotech firms strive for autonomy while bringing first-in-class drugs to market.On an infectious disease front, Merck has demonstrated significant progress with its HIV treatment Islatravir in Phase 3 trials. This places Islatravir as a potential competitor against Gilead's Biktarvy, showcasing ongoing innovation within antiviral drug development.Additionally, Dexcom has gained clearance for its type 2 diabetes software integrating continuous glucose monitoring technology. This advancement exemplifies how digital health technologies are transforming chronic disease management bySupport the show
In this Mol Bio Minutes episode, Thermo Fisher Scientific's Monika Jazdauskaitė dives into the versatile world of Recombinase Polymerase Amplification (RPA). Unlike PCR, RPA operates at a constant, low temperature (around 37–42°C), enabling fast, equipment-light workflows that are ideal for field diagnostics and decentralized labs. Monika explains how the method works and why RPA is emerging as a go-to technique for both DNA and RNA target detection.She highlights RPA's specificity, sensitivity, and robustness against common inhibitors like ethanol and heparin, critical for applications like respiratory pathogen detection or low-quality sample inputs. Plus, she shares how RPA's gentle conditions and lyophilization compatibility make it a strong candidate for stabilizing next-generation sequencing (NGS) libraries, especially those with high GC content.Whether you're looking to simplify pathogen detection or streamline your sequencing prep, RPA offers a compelling alternative to traditional amplification. And with ready-to-use kits like the Invitrogen™ Lyo-ready RPA Kit, Thermo Fisher is helping researchers bring speed and stability to molecular workflows, all with no thermal cycler required. Subscribe to get future episodes as they drop and if you like what you're hearing we hope you'll share a review or recommend the series to a colleague. Visit the Invitrogen School of Molecular Biology to access helpful molecular biology resources and educational content, and please share this resource with anyone you know working in molecular biology. For Research Use Only. Not for use in diagnostic procedures.
Since the late 19th century, the concept of an "alien invasion" has been a recurring theme in literature, and also served as a kind of cultural pressure gauge—it reveals our fears about what might be lurking in the cosmos, as well as the everyday horrors of the human condition, forcing us to confront questions about our vulnerabilities, and our assumptions about intelligent life elsewhere in the universe. This week on The Micah Hanks Program, we lead off with a bit of discussion about the persistent rumors about the interstellar comet 3I/ATLAS, and whether its presence could actually bring the discussion about alien visitation out of fiction and into reality. Then, we shift our attention to the discussion about what a real alien invasion might entail, and what it could mean for life on Earth if it were ever to occur; would humanity be up to the task of defending against a cosmic threat from beyond the stars? Have you had a UFO/UAP sighting? Please consider reporting your sighting to the UAP Sightings Reporting System, a public resource for information about sightings of aerial phenomena. The story doesn't end here... become an X Subscriber and get access to even more weekly content and monthly specials. Want to advertise/sponsor The Micah Hanks Program? We have partnered with the AdvertiseCast to handle our advertising/sponsorship requests. If you would like to advertise with The Micah Hanks Program, all you have to do is click the link below to get started: AdvertiseCast: Advertise with The Micah Hanks Program Show Notes Below are links to stories and other content featured in this episode: NEWS: Grandest Thanksgiving Yet? 2025 Holiday To Cost Average American Up To $1,000 Pranksters bypass Louvre's security and sneak painting in Oldest sequenced RNA reveals details about a mammoth's final moments 40,000 years ago Archaeological breakthrough contradicts the timeline of human civilization 3I/ATLAS: The Harvard Scientist, Kim Kardashian and the Comet That Probably Isn't an Alien Spaceship INVADERS: Increased UFO Reports Aren't Aliens, But Earth Is Still Unprepared for an Alien Invasion Aliens may have stopped trying to contact humans because they simply got bored, Nasa scientist claims Mind of its own: Will "general AI" be like an alien invasion? BECOME AN X SUBSCRIBER AND GET EVEN MORE GREAT PODCASTS AND MONTHLY SPECIALS FROM MICAH HANKS. Sign up today and get access to the entire back catalog of The Micah Hanks Program, as well as "classic" episodes, weekly "additional editions" of the subscriber-only X Podcast, the monthly Enigmas specials, and much more. Like us on Facebook Follow @MicahHanks on X. Keep up with Micah and his work at micahhanks.com.
这是一期与《科技早知道》的串台节目2024 年的诺贝尔化学奖是颁给了三位在蛋白质结构预测和蛋白质设计领域作出开创性贡献的科学家。这标志着 AI 已经成为生命科学的核心工具 ，正在改变我们理解生命的方式和重塑药物研发的未来。我们今天的嘉宾是深圳湾实验室的周耀旗教授，他是这场变革的亲历者和推动者之一。他最初在学术界专注于蛋白质结构预测，后来他敏锐地意识到 RNA 领域的潜力与挑战，将研究方向转向 RNA 结构预测。现在他又走上创业之路，带领团队开发 以 RNA 为靶点的小分子药物，探索如何将基础研究真正转化为新的疗法。今天的节目我们聊一聊作为蛋白质结构预测工具的 AlphaFold3，它的突破与局限在哪里？RNA为什么是新一代药物的重要靶点？以及 AI 在新药研发中的作用究竟是什么?【本期人物】周耀旗，深圳湾实验室资深研究员，砺博生物科学创始人【时间戳】02:42 为什么蛋白质结构如此重要？解析蛋白结构是理解生命机器的关键05:47 蛋白质结构预测简史：基于模板 --> 碎片拼接 --> 二面角+距离预测14:26 「1+2=3」：AlphaFold 革命性飞跃的背后17:40 结构生物学家会不会被替代？聊聊 AlphaFold 还做不了的事23:26 RNA 结构预测为何更难？仅4个碱基，结构不稳定，已知数据稀缺29:24 蛋白质只是「提线木偶」，RNA 才是「操纵者」31:56 从靶向蛋白到靶向 RNA -- HIV蛋白酶抑制剂的成功和 KRAS 蛋白的「光滑锁眼」的难题35:49 靶向 RNA 药物的里程碑：首个靶向 RNA 的小分子药利司扑兰（Risdiplam）38:50 在缺乏结构数据的情况下，如何开发靶向 RNA 的药物？43:06 AI 在新药研发中的真实作用：是加速器，而非革命45:39 AI for Science：摆脱数据依赖，回归物理，寻找分子世界的「牛顿定律」
Send us a textGood morning from Pharma Daily, the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of groundbreaking changes and innovations reshaping the landscape of drug development, clinical trials, and regulatory affairs.In a major move, Pfizer has successfully outbid Novo Nordisk to acquire Metsera for $10 billion. This strategic acquisition aims to bolster Pfizer's presence in the obesity treatment market by leveraging Metsera's GLP-1 receptor agonist technology. This acquisition underscores the continuing trend of consolidation within the pharmaceutical industry, enhancing competitive market positioning and reflecting a broader quest for novel therapeutic solutions.Eli Lilly has entered into a $1.2 billion collaboration with Sangenebio to advance RNA interference (RNAi) therapeutics targeting metabolic diseases. This partnership marks a pivotal shift towards utilizing RNAi technology to silence disease-causing genes, representing significant progress in metabolic disease treatment. The focus on innovative delivery mechanisms and targeted interventions is critical for accelerating drug development and enhancing therapeutic efficacy.Onchilles Pharma's recent Series A1 funding round, securing $25 million, marks a notable advancement in oncology therapeutics. The company's focus on dual-action cancer biologics targeting the ELANE pathway offers promising insights into immune activation in solid tumors. This investment exemplifies the growing interest in biologic therapies that provide targeted cancer treatments, potentially leading to more effective options for patients.Regulatory advancements are also making headlines. Chongqing Precision Biotech has received approval for Pujiolunxi, a treatment for pediatric relapsed or refractory B-cell acute lymphoblastic leukemia (ALL), broadening therapeutic options for this challenging pediatric condition. Furthermore, Alembic Pharmaceuticals' generic version of Dasatinib tablets has gained FDA approval for Philadelphia chromosome-positive chronic myeloid leukemia, increasing accessibility to treatment.Several promising clinical trial results have emerged recently. Summit Therapeutics and Akeso Biopharma's Ivonescimab showed a 26% overall survival benefit in phase 3 trials for non-small-cell lung cancer. The potential of bispecific antibodies in combination therapies is gaining attention for its efficacy in difficult-to-treat cancers. Additionally, Regeneron's Dupixent has achieved phase 3 success in treating allergic fungal rhinosinusitis, reinforcing its role as a versatile treatment option across various inflammatory diseases.Advancements in cardiovascular therapeutics also continue to unfold. Merck & Co.'s Enlicitide Decanoate demonstrated over 50% LDL cholesterol reduction in a phase 3 study focused on atherosclerotic cardiovascular disease through PCSK9 inhibition. AstraZeneca's Baxdrostat showed significant blood pressure reduction in trials targeting treatment-resistant hypertension, highlighting the potential impact of aldosterone synthase inhibitors on cardiovascular health.The investment landscape remains robust with substantial fundraising activities such as Elephas Biosciences' $40 million Series B-2 for commercializing their live tumor profiling platform and Iambic's over $100 million series focused on AI-driven drug discovery. These investments underscore the industry's commitment to integrating advanced technologies like AI and live tumor profiling to enhance precision medicine capabilities.FDA regulatory updates are pivotal as well, notably with the decision to lift warning labels from hormone replacement therapy (HRT) products following an expert review that found previous warnings were based on misinformation regaSupport the show
BUFFALO, NY - November 10, 2025 – A new #research paper was #published in Oncotarget (Volume 16) on November 6, 2025, titled “Anti-DNA virus agent cidofovir - loaded green synthesized cerium oxide nanoparticles (Nanoceria): Nucleic acids (DNA and RNA) binding affinity and cytotoxicity effects.” In this study, led by Nahid Shahabadi from Razi University in Kermanshah, researchers developed an environmentally friendly approach to enhance the performance of cidofovir, a drug used to treat infections caused by DNA viruses. The work responds to the growing need for therapies that are safer, more effective, and better targeted. The research team developed a new compound by loading cidofovir onto green-synthesized cerium oxide nanoparticles (nanoceria), known as CDV-CeO2 NPs. This method combines the drug's antiviral and anticancer properties with the biological activity of nanoceria, which is known for its antioxidant, anti-inflammatory, and tumor-targeting effects. To avoid toxic chemicals, the nanoparticles were synthesized using quince fruit peel extract, making the process more sustainable and suitable for medical applications. Laboratory experiments showed that the CDV-CeO2 nanoparticles were significantly more effective at killing breast cancer cells than either cidofovir or cerium oxide nanoparticles alone. At the highest tested concentration, the new compound destroyed more than 97% of cancer cells, compared to 72% with cidofovir alone and 50% with nanoparticles alone. These findings suggest that the combined formulation enhances anticancer activity and may allow for lower drug doses with fewer side effects. To understand how these nanoparticles interact with genetic material, the team studied their binding to DNA and RNA, two key molecules involved in cancer development and viral replication. CDV-CeO2 nanoparticles showed strong binding affinity through two mechanisms: groove binding, which fits into natural curves of the genetic molecule strands, and intercalation, which inserts between base pairs. The nanoparticles formed stable complexes that responded to temperature, indicating reliable interactions in biological systems. “The novelty of this work lies in the innovative green synthesis method, the dual-functional therapeutic application, and the enhanced biological activity of the CDV-CeO2 NPs, which collectively position these nanoparticles as promising candidates for future cancer and antiviral therapies.” This research presents a potential new strategy for improving drug targeting and delivery using green nanotechnology. The approach could lead to more effective treatments for diseases such as breast cancer and infections caused by human papillomavirus (HPV) and other DNA viruses. However, further research, including animal and clinical studies, is needed to confirm the safety and long-term effectiveness of this treatment. Overall, this study represents a significant step toward combining natural materials with nanomedicine to create more efficient therapies. If supported by future research, CDV-CeO2 nanoparticles could offer a new generation of dual-action treatments. DOI - https://doi.org/10.18632/oncotarget.28774 Correspondence to - Nahid Shahabadi - nahidshahabadi@yahoo.com Abstract video - https://www.youtube.com/watch?v=Il9CsfgO2mU Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us on social media: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM
From the mind of Vince Gilligan (Breaking Bad, Better Call Saul) comes the most original sci-fi premiere in years. In Episodes 1 & 2 of Pluribus (“We Is Us” and “Pirate Lady”), a rogue radio signal from deep space triggers a global transformation — and only one person is left unconnected: speculative romance author Carol Sturka, played by a powerhouse Rhea Seehorn.Brandon & Chanel dive into everything you missed:The alien RNA signal that infects the world via… saliva and donutsRhea Seehorn's brilliant performance as the reluctant resistanceThe arrival of Pirate Lady, a real-life version of Carol's book characterHelen's tragic death and what it means to “join” the hivemindSeizures triggered by Carol's emotions (that may have killed 11 million people
Upgrade your biology in 10 minutes with this week's rundown from Dave Asprey. This episode breaks down the six biggest stories in biohacking and health tech, from sleep hormones to mitochondrial rejuvenation, giving you the data you need to live longer, think faster, and perform at your peak. This episode covers: • The Melatonin Heart Warning Everyone Missed A major new study from the American Heart Association reveals that long-term melatonin users face nearly twice the risk of heart failure and 3.5 times higher hospitalization rates. Once considered a harmless sleep aid, melatonin's hormonal effects may disrupt cardiovascular recovery, testosterone, and blood pressure regulation when used nightly. The takeaway: melatonin is a short-term circadian reset tool, not a forever supplement. Source: American Heart Association — newsroom.heart.org/news/long-term-use-of-melatonin-supplements-to-support-sleep-may-have-negative-health-effects • Bryan Johnson's Extreme Microplastics Detox Biohacker Bryan Johnson shared lab-verified results showing an 85% reduction in microplastics in his semen after one year of daily 200°F dry saunas followed by ice packs on the groin. It's not peer reviewed yet, but it'ssparking global discussion about environmental toxins, fertility, and detoxification. Whether or not you follow his protocol, this study highlights how widespread microplastics have become and how heat, sweat, and smarter exposure control may help fight back. Source: New York Post — nypost.com/2025/10/23/health/biohacker-bryan-johnson-got-rid-of-85-of-microplastics-from-his-semen • Urolithin A: The Mitochondrial Molecule That Strengthens Immunity A peer-reviewed human trial published in Nature Aging found that four weeks of daily Urolithin A (Mitopure®) supplementation improved immune function in adults aged 45–70, increasing youthful CD8 T-cells, natural killer cells, and mitochondrial performance inside immune cells. By triggering mitophagy, your body's cleanup process for old mitochondria, Urolithin A enhances energy, resilience, and immune strength. It's the clearest evidence yet that we can modulate immune aging through mitochondrial renewal. Head to timeline.com/dave to get 10% off your first order. Source: BioSpace — biospace.com/press-releases/timeline-continues-to-build-the-most-clinically-researched-longevity-products-targeting-immune-brain-and-muscle-aging • Google's New AI Model That “Talks” to Cells Google DeepMind and Yale launched Cell2Sentence-Scale, an open-source AI model that lets scientists query cellular pathways in natural language. The system can predict how cells transition from healthy to cancerous states and identify molecular switches that might reverse those changes. It's compressing years of biology into days and democratizing research for small labs and independent scientists alike. Isn't AI a beautiful thing? Source: Google DeepMind — blog.google/technology/ai/google-gemma-ai-cancer-therapy-discovery • Omega-3s Calm the Brain and the Temper A massive new meta-analysis of randomized controlled trials shows omega-3 fatty acids (EPA and DHA) reduce aggression by up to 28%. That includes both reactive anger and planned aggression. By lowering neuroinflammation and stabilizing cell membranes, omega-3s appear to balance dopamine and serotonin, proving that healthy fats aren't just heart food, they're emotional regulators too. Source: Science Alert — sciencealert.com/one-dietary-supplement-was-shown-to-reduce-aggression-by-up-to-28 • Chronic Fatigue Syndrome Finally Gets a Biomarker For the first time, researchers have developed a blood test that accurately identifies chronic fatigue syndrome (ME/CFS) using DNA methylation and micro-RNA expression patterns. This breakthrough distinguishes CFS from other autoimmune and viral conditions, marking a turning point for millions of patients long dismissed by traditional medicine. It's proof that data-driven diagnostics can transform how we understand mystery illnesses. Source: Science Daily — sciencedaily.com/releases/2025/11/251102205021.htm All source links provided for easy reference to the original reporting and research above. This is essential listening for fans of biohacking, hacking human performance, functional medicine, and longevity who want actionable tools from Host Dave Asprey and a guest who embodies what it means to age with energy, clarity, and vitality. Dave Asprey is a four-time New York Times bestselling author, founder of Bulletproof Coffee, and the father of biohacking. With over 1,000 interviews and 1 million monthly listeners, The Human Upgrade brings you the knowledge to take control of your biology, extend your longevity, and optimize every system in your body and mind. Each episode delivers cutting-edge insights in health, performance, neuroscience, supplements, nutrition, biohacking, emotional intelligence, and conscious living. New episodes are released every Tuesday, Thursday, Friday, and Sunday (BONUS). Dave asks the questions no one else will and gives you real tools to become stronger, smarter, and more resilient. Keywords: melatonin heart risk, sleep hormones, microplastics detox, Bryan Johnson, Urolithin A, mitophagy, mitochondrial health, immune aging, DeepMind AI, cellular modeling, omega-3 aggression, neuroinflammation, chronic fatigue biomarker, ME/CFS test, biohacking news, longevity research Thank you to our sponsors! -LYMA | Go to https://lyma.sjv.io/gOQ545 and use code DAVE10 for 10% off the LYMA Laser.-Vibrant Blue Oils | Grab a full-size bottle for over 50% off at https://vibrantblueoils.com/dave. Resources: • Danger Coffee: https://dangercoffee.com/discount/dave15 • My Daily Supplements: SuppGrade Labs (15% Off) • Favorite Blue Light Blocking Glasses: TrueDark (15% Off) • Dave Asprey's BEYOND Conference: https://beyondconference.com • Dave Asprey's New Book – Heavily Meditated: https://daveasprey.com/heavily-meditated • Upgrade Collective: https://www.ourupgradecollective.com • Upgrade Labs: https://upgradelabs.com • 40 Years of Zen: https://40yearsofzen.com Timestamps: 0:00 — Intro 0:18 — Story 1: Melatonin & Heart Health 1:58 — Story 2: Microplastics Detox 3:39 — Story 3: Urolithin A & Immune Function 5:19 — Story 4: AI Cell Model 6:57 — Story 5: Omega-3 & Aggression 8:43 — Story 6: CFS Blood Test 9:59 — Weekly Upgrade Protocol See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
Discover how biotech and healthcare teams are fast-tracking research and development through AI and high-performance cloud infrastructure. Ross Katz sits down with Hugo Shi of Saturn Cloud and Ilya Burkov of Nebius to explore scalable, secure solutions for GPU-heavy AI workloads. From compliance to cost savings, this episode unpacks what it takes to innovate at scale in life sciences. What You'll Learn in This Episode: >> Why AI workloads in biotech demand specialized infrastructure >> How Saturn Cloud and Nebius simplify compliance, scale, and security for life sciences >> Real-world examples of gene editing, RNA sequencing, and medical imaging powered by cloud AI >> The trade-offs between hyperscalers and NeoClouds for GPU availability and cost >> Strategies for deploying, optimizing, and managing large-scale AI models Meet Our Guests Hugo Shi is the CTO and Founder of Saturn Cloud and a co-founder of Anaconda. He brings deep expertise in data science, AI infrastructure, and open-source development, helping teams scale complex workloads with minimal friction. Ilya Burkov is Global Head of Healthcare & Life Sciences Growth at Nebius. With a background in medicine and cloud technology, Ilya leads strategy and partnerships to empower biotech teams with secure, high-performance compute solutions. About The Host Ross Katz is Principal and Data Science Lead at CorrDyn. Ross specializes in building intelligent data systems that empower biotech and healthcare organizations to extract insights and drive innovation. Connect with Our Guest: Sponsor: CorrDyn, a data consultancyConnect with Hugo Shi on LinkedIn Connect with IIya Burkov on LinkedIn Connect with Us: Follow the podcast for more insightful discussions on the latest in biotech and data science.Subscribe and leave a review if you enjoyed this episode!Connect with Ross Katz on LinkedIn Sponsored by… This episode is brought to you by CorrDyn, the leader in data-driven solutions for biotech and healthcare. Discover how CorrDyn is helping organizations turn data into breakthroughs at CorrDyn.
Ερευνητές από τη Βικτώρια, έχουν αναπτύξει το πρώτο φάρμακο τεχνολογίας RNA στον κόσμο, για την «πάθηση του λύκου». Μια αυτοάνοση ασθένεια που επηρεάζει περίπου 20.000 Αυστραλούς. Πρόκειται για μια κρέμα, η οποία χρησιμοποιείται επιδερμικά, προκειμένου να αντιμετωπίσει τα σοβαρά συμπτώματα που προκαλεί η εν λόγω πάθηση, όπως πόνο στις αρθρώσεις, κόπωση και φλεγμονή των κύριων οργάνων.
Broadcast from KSQD, Santa Cruz on 10-30-2025: Dr. Dawn opens with Halloween-themed scary medical stories, beginning with food toxins lurking in refrigerators and pantries. She explains how molds on grains and nuts, particularly Aspergillus species, produce aflatoxins that bind to DNA and cause liver cancer, making peanuts especially risky. Fusarium on wheat produces trichothecenes and fumonisins damaging cell membranes. Penicillium molds on fruits like apples produce patulin creating reactive oxygen species that harm organs. She advises discarding soft moldy foods entirely since fungal hyphae penetrate deeply, while hard cheeses can have moldy portions cut away. Meat spoilage involves bacteria producing cadaverine and putrescine, with E. coli, Campylobacter, Salmonella, and Clostridium causing severe illness through heat-stable toxins. A caller asks about yogurt-covered peanuts tasting rancid and confirms Botox contains botulinum toxin A in different salt forms, used medically for migraines, hyperhidrosis, and strabismus. The caller also describes paper-thin skin on sun-exposed forearms that bleeds easily. Dr. Dawn explains UV radiation damages collagen and elastin, making blood vessels vulnerable to shear forces. She recommends topical vitamin K products like Dermal K and protective lycra sleeves or gardening gauntlets to prevent injuries, emphasizing the need for annual dermatologic exams after extensive sun exposure. An emailer asks about RSV vaccine recommendations before overseas travel. Dr. Dawn disagreed with the couple's physician, citing US Preventive Services Task Force guidelines recommending RSV vaccination for all adults 60 and older, plus those 50+ with chronic conditions. She discusses FDA-approved home testing options including the PIXEL by LabCorp test for COVID, flu, and RSV, and iHealth rapid tests. She notes RSV point-of-care tests are available to medical practitioners and recommends thorough vaccination before international trips. Dr. Dawn presents a frightening investigation into private equity hospital bankruptcies, focusing on Steward Healthcare's 31 hospitals and Prospect's 16 facilities. Private equity firm Cerberus earned $700 million while Steward 650 documented incidents of deficient care including deaths. One woman died from hemorrhage after vendors repossessed equipment due to unpaid bills. She explains the shell game where companies sell hospital land to Medical Properties Trust, forcing new operators to pay rent while private equity extracts profits. The Brookings Institution study reveals systematic prioritization of investor returns over patient care, with courts failing to prevent these practices despite some states passing protective legislation. She discusses stillbirth rates being significantly underreported, with Harvard research showing actual rates of 1 in 147 pregnancies versus CDC's 1 in 175, worsening to 1 in 95 for black families. Over 70% involved known risks like obesity or diabetes, but 30% had no identifiable factors. Dr. Dawn emphasizes unconscious bias in medicine where women's complaints are dismissed, particularly affecting women of color and non-English speakers, noting both patient and provider biases require training to address. Dr. Dawn warns about HPV-related oral squamous cell carcinoma in young men, explaining that changing sexual practices over 30 years have created new transmission routes from genitals to mouth. Major risk factors include smokeless tobacco and hard alcohol which damage DNA. She mentions newly available saliva tests for persistent HPV detection, recommending risk factor reduction for positive cases. She concludes optimistically with a breakthrough Huntington's disease treatment using microRNA molecule AMT-130 delivered via virus to brain striatum. The treatment mirrors toxic Huntington protein's RNA, creating double-stranded structures cells destroy, preventing toxic protein accumulation. The three-year trial of 29 patients showed 75% slowing of disease progression with few side effects, offering hope for 100,000 Americans carrying the mutation, including 40,000 with current symptoms.
Dr. Yuri Maricich, Chief Medical Officer at CAMP4 Therapeutics, describes regulatory RNA, a new area of biology that recognizes the role of Reg RNA in the production of proteins from specific genes. This technology is well-suited for haploinsufficient diseases such as SYNGAP1-related disorders, in which there is a lack of healthy protein and both parents carry a copy of the mutated gene. The goal is to create disease-modifying treatments that correct the underlying genetic cause rather than treating the symptoms. Yuri explains, "What was really unique about CAMP4's scientific approach is that we're focused on a whole new and emerging area of biology called regulatory RNA. And these are control elements for the expression of genes. In other words, how much protein we get from a particular gene. And there's been a lot of work in the past on how to have less protein made, particularly if it's a protein that has a mutation that causes a problem. But in medicine, there have been very few opportunities to actually increase the amount of protein, but there are many diseases that need more healthy protein." "The backdrop of CAMP4 is that there was work done just over eight years ago at the Whitehead Institute at the Massachusetts Institute of Technology in a lab by Rick Young, and he was working with a colleague at Boston Children's Hospital, Lenson, and they noticed that there was this group of so-called regRNAs. These were non-coding regions that historically have been really ignored. And as they looked and explored their function further, what they discovered was that, in fact, these regRNA elements play a critical role in controlling how much protein is produced. And so the story of CAMP4 has been to continue to understand and map different cell lines so that we could take a particular target gene and, by using tools or established medicines, for example, like antisense oligonucleotides, we could actually increase the amount of a gene's protein back up to normal." #CAMP4 #CAMP4Therapeutics #SYNGAP1 #CuresSYNGAP1 #regRNA #RegulatoryRNA camp4tx.com Download the transcript here
Dr. Yuri Maricich, Chief Medical Officer at CAMP4 Therapeutics, describes regulatory RNA, a new area of biology that recognizes the role of Reg RNA in the production of proteins from specific genes. This technology is well-suited for haploinsufficient diseases such as SYNGAP1-related disorders, in which there is a lack of healthy protein and both parents carry a copy of the mutated gene. The goal is to create disease-modifying treatments that correct the underlying genetic cause rather than treating the symptoms. Yuri explains, "What was really unique about CAMP4's scientific approach is that we're focused on a whole new and emerging area of biology called regulatory RNA. And these are control elements for the expression of genes. In other words, how much protein we get from a particular gene. And there's been a lot of work in the past on how to have less protein made, particularly if it's a protein that has a mutation that causes a problem. But in medicine, there have been very few opportunities to actually increase the amount of protein, but there are many diseases that need more healthy protein." "The backdrop of CAMP4 is that there was work done just over eight years ago at the Whitehead Institute at the Massachusetts Institute of Technology in a lab by Rick Young, and he was working with a colleague at Boston Children's Hospital, Lenson, and they noticed that there was this group of so-called regRNAs. These were non-coding regions that historically have been really ignored. And as they looked and explored their function further, what they discovered was that, in fact, these regRNA elements play a critical role in controlling how much protein is produced. And so the story of CAMP4 has been to continue to understand and map different cell lines so that we could take a particular target gene and, by using tools or established medicines, for example, like antisense oligonucleotides, we could actually increase the amount of a gene's protein back up to normal." #CAMP4 #CAMP4Therapeutics #SYNGAP1 #CuresSYNGAP1 #regRNA #RegulatoryRNA camp4tx.com Listen to the podcast here
00:47 How bowhead whales live so longResearchers have uncovered a protein that enhances DNA repair and may explain how bowhead whales can live more than 200 years. The protein, cold-induced RNA-binding protein, was shown to enhance repair of double stranded DNA breaks, a particularly troublesome kind of damage. The team showed that this protein could also extend the lives of Drosophila flies and enhance repair in human cells. More needs to be understood about how this protein works, but the researchers hope that it could, one day, help prevent cancer and ageing in humans.Research Article: Firsanov et al.News: This whale lives for centuries: its secret could help to extend human lifespan11:22 Research HighlightsA precise way to grow crystals, with lasers — plus, the specialist organ that allows stinkbugs to protect their eggs from wasps.Research Highlight: How to grow crystals when and where you want themResearch Highlight: Stinkbug ‘ear' actually hosts parasite-fighting fungi13:31 An antivenom against a broad range of snakebitesResearchers have used ‘nanobodies' to create an antivenom that works against 17 snake species' venom. Snakebites kill millions each year, so getting the right antivenom can be life or death. But they are difficult to produce and often are very specific. Now, using nanobodies from llamas, researchers created an antivenom against a broad range of snake species' venom. The new antivenom can now even be produced without the llamas, and the team hope it will pave the way for a more universal antivenom.Research Article: Ahmadi et al.Subscribe to Nature Briefing, an unmissable daily round-up of science news, opinion and analysis free in your inbox every weekday. Hosted on Acast. See acast.com/privacy for more information.
Novartis' biggest deal in more than a decade gives the Swiss pharma three programs for muscular dystrophies that are close to the finish line. On the latest BioCentury This Week podcast, BioCentury's analysts discuss the $12 billion deal for Avidity in the context of Novartis' recent acquisitions and the antibody-oligonucleotide conjugate platform it is gaining.The team dives into RNA versus DNA modalities, noting antisense and siRNA approaches appear to be gaining traction with major pharmas as traditional gene therapy and gene editing approaches hit rocky times. Still, they note hopeful progress among base editing therapies given the promising early track records of over a dozen base editors in the clinic. They also discuss BioCentury's conversation with base editing inventor David Liu; Alkermes' $2.1 billion acquisition of Avadel; and β-catenin data from Parabilis. This episode of BioCentury This Week is sponsored by Evotec.View full story: https://www.biocentury.com/article/657412#AntibodyOligonucleotideConjugates #RNAtherapeutics #BaseEditing #MuscularDystrophy #WntPathway #BetaCatenin #Orexin2Receptor #PrecisionMedicine00:01 - Sponsor Message: Evotec 02:04 - 12th China Healthcare Summit08:11 - Novartis' $12B Deal16:58 - Alkermes M&A20:01 - David Liu Base Editing25:02 - Parabilis' DataTo submit a question to BioCentury's editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text
Varroa mites remain the most destructive pest facing honey bees today—but a revolutionary new treatment may finally shift the balance. In this episode, Jeff Ott and Dr. Becky Masterman welcome Adam Pachl, North American Technical Manager for Bee Health at GreenLight Biosciences, to discuss Norroa, the first EPA-approved dsRNA-based treatment for Varroa mites. Norroa introduces a fundamentally new approach: instead of killing mites outright, it prevents them from reproducing. Adam explains how this RNA interference (RNAi) technology works at the molecular level, blocking the mites' ability to lay viable eggs without harming honey bees or other organisms. He also shares insights from years of field research, including trials across five U.S. states that demonstrated dramatic improvements in colony survival and mite suppression. Becky and Jeff explore the implications of this technology for beekeepers of all scales—from hobbyists managing a few hives to large-scale commercial operations—and how Norroa fits into an integrated pest management strategy. The discussion covers everything from timing of application, compatibility with other treatments, and safety testing, to potential future uses of RNAi against pests like Tropilaelaps. For the first time in decades, beekeepers may have a tool that targets Varroa precisely and safely—without collateral damage to the bees they're fighting to protect. Websites from the episode and others we recommend: GreenLight Biosciences. “GreenLight Biosciences Launches Norroa, the First RNA-Based Treatment for Varroa Mites.” 25 Sep 2025. https://www.greenlightbiosciences.com/articles/greenlight-biosciences-launches-norroa-the-first-rna-based-treatment-for-varroa-mites GreenLight Biosciences. “In the Pipeline: Protecting the Honeybee.” https://www.greenlightbiosciences.com/in-the-pipeline-protecting-the-honeybee GeneOnline. “EPA Registers Norroa as First RNA-Based Treatment for Varroa Mites Threatening Honeybee Populations.” 25 Sept 2025. https://www.geneonline.com/epa-registers-norroa-as-first-rna-based-treatment-for-varroa-mites-threatening-honeybee-populations Honey Bee Obscura Podcast: https://honeybeeobscura.com Project Apis m. (PAm): https://www.projectapism.org Honey Bee Health Coalition: https://honeybeehealthcoalition.org The National Honey Board: https://honey.com Honey Bee Obscura Podcast: https://honeybeeobscura.com Copyright © 2025 by Growing Planet Media, LLC ______________ Betterbee is the presenting sponsor of Beekeeping Today Podcast. Betterbee's mission is to support every beekeeper with excellent customer service, continued education and quality equipment. From their colorful and informative catalog to their support of beekeeper educational activities, including this podcast series, Betterbee truly is Beekeepers Serving Beekeepers. See for yourself at www.betterbee.com This episode is brought to you by Global Patties! Global offers a variety of standard and custom patties. Visit them today at http://globalpatties.com and let them know you appreciate them sponsoring this episode! Thanks to Bee Smart Designs as a sponsor of this podcast! Bee Smart Designs is the creator of innovative, modular and interchangeable hive systems made in the USA using recycled and American sourced materials. Bee Smart Designs - Simply better beekeeping for the modern beekeeper. Give your bees a boost with HiveAlive! Proven to increase bee health, honey yield, and overwinter survival, HiveAlive's unique formula includes seaweed, thyme, and lemongrass, making it easy to feed. Choose from HiveAlive's Fondant Patties, High-Performance Pollen Patties, or EZ Feed Super Syrup—ready-to-use options for busy beekeepers. Buy locally or online. HiveIQ is revolutionizing the way beekeepers manage their colonies with innovative, insulated hive systems designed for maximum colony health and efficiency. Their hives maintain stable temperatures year-round, reduce stress on the bees, and are built to last using durable, lightweight materials. Whether you're managing two hives or two hundred, HiveIQ's smart design helps your bees thrive while saving you time and effort. Learn more at HiveIQ.com. Thanks to Strong Microbials for their support of Beekeeping Today Podcast. Find out more about their line of probiotics in our Season 3, Episode 12 episode and from their website: https://www.strongmicrobials.com Thanks for Northern Bee Books for their support. Northern Bee Books is the publisher of bee books available worldwide from their website or from Amazon and bookstores everywhere. They are also the publishers of The Beekeepers Quarterly and Natural Bee Husbandry. _______________ We hope you enjoy this podcast and welcome your questions and comments in the show notes of this episode or: questions@beekeepingtodaypodcast.com Thank you for listening! Podcast music: Be Strong by Young Presidents; Epilogue by Musicalman; Faraday by BeGun; Walking in Paris by Studio Le Bus; A Fresh New Start by Pete Morse; Wedding Day by Boomer; Christmas Avenue by Immersive Music; Red Jack Blues by Daniel Hart; Original guitar background instrumental by Jeff Ott. Beekeeping Today Podcast is an audio production of Growing Planet Media, LLC ** As an Amazon Associate, we may earn a commission from qualifying purchases Copyright © 2025 by Growing Planet Media, LLC
Upgrade your biology in 10 minutes with this week's rundown from Dave Asprey. This episode breaks down the five biggest stories in biohacking and health-tech — from genetic rejuvenation to your future digital twin — giving you the tools to live longer, perform better, and stay ahead of the curve.This episode covers:• Vitamin D as the Surprising “Anti-Aging Pill”A new five-year randomized study shows that daily 2,000 IU vitamin D supplementation slowed telomere shortening by 140 base pairs compared to placebo, translating to measurable gains in biological youth. Vitamin D isn't just for bones anymore — it's a foundational longevity molecule.Source: Science Daily — https://www.sciencedaily.com/releases/2025/10/251022023132.htm• The Supercentenarian Gene That Rejuvenates Old HeartsResearchers at the University of Bristol identified a gene variant, LAV-BPIFB4, common among people living past 100, that reversed cardiac aging in animal studies — restoring blood flow, heart strength, and tissue repair with a single treatment. It's a glimpse into how gene therapy could soon democratize superhuman longevity.Source: University of Bristol News — https://www.bristol.ac.uk/news/2025/october/progeria.html• FDA Closes the “GRAS” Loophole — Supplements Enter a New EraThe FDA just ended decades of self-certification for new dietary ingredients, requiring full agency review for anything entering the market. It's the biggest shakeup in supplement regulation in years — raising quality, accountability, and trust across the entire industry.Source: Mintz FDA Flux Newsletter — https://www.mintz.com/insights-center/viewpoints/2791/2025-10-16-fda-flux-october-2025-newsletter• Microbes That Trigger Autophagy — Your Gut as an Anti-Aging SwitchScientists at the University of Basel discovered that certain dietary bacteria containing double-stranded RNA can directly trigger autophagy, the body's built-in cell-recycling system. Fermented foods like kimchi, kefir, and sauerkraut may now be proven longevity tools for activating repair from the inside out.Source: University of Basel — https://www.unibas.ch/en/News-Events/News/Uni-Research/Longevity-research—Dietary-stress-supports-healthy-aging.htmlFurther reading: Neuroscience News — https://neurosciencenews.com/dietary-rna-cellular-aging-29757/• Your Medical Avatar Is Coming — The Digital Twin of YouForbes reports on the rise of personalized “medical avatars” — AI-powered digital twins built from your wearables and biometrics that can predict health risks, recommend interventions, and evolve alongside your biology. Doctors like Daniel Kraft call it generative health — a revolution in predictive medicine where your data literally becomes your doctor.Source: Forbes Innovation — https://www.forbes.com/sites/johnwerner/2025/10/21/wearables-ai-and-your-personal-medical-avatar/This is essential listening for fans of biohacking, human performance, functional medicine, and longevity sciencewho want real, actionable tools from Dave Asprey — the father of biohacking and founder of Bulletproof Coffee.With over 1,000 interviews and 1 million monthly listeners, The Human Upgrade brings you the knowledge to take control of your biology, extend your lifespan, and upgrade every system in your body and mind.New episodes drop every Tuesday, Thursday, Friday, and Sunday. Dave asks the questions no one else will — and gives you the science-backed tools to become stronger, smarter, and more resilient.Keywords: vitamin D longevity, telomeres, BPIFB4 gene, cardiac rejuvenation, supplement regulation, GRAS FDA, autophagy, microbiome, fermented foods, biohacking news, medical avatar, digital twin, predictive medicine, Daniel Kraft, quantum health, wearable AI, Dave Asprey, The Human UpgradeThank you to our sponsors! TRU KAVA | Go to https://trukava.com/ and use code DAVE10 for 10% off.HeartMath | Go to https://www.heartmath.com/dave to save 15% off.Timestamps: 0:00 — Introduction0:18 — Story 1: Vitamin D & Telomeres1:02 — Story 2: Longevity Gene Therapy1:49 — Story 3: FDA Supplement Reform2:38 — Story 4: Gut Bacteria & Autophagy3:46 — Story 5: Medical Avatars4:53 — Weekly Protocol5:42 — OutroSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
2024 年的诺贝尔化学奖是颁给了三位在蛋白质结构预测和蛋白质设计领域作出开创性贡献的科学家。这标志着 AI 已经成为生命科学的核心工具 ，正在改变我们理解生命的方式和重塑药物研发的未来。 我们今天的嘉宾是深圳湾实验室的周耀旗教授，他是这场变革的亲历者和推动者之一。他最初在学术界专注于蛋白质结构预测，后来他敏锐地意识到 RNA 领域的潜力与挑战，将研究方向转向 RNA 结构预测。现在他又走上创业之路，带领团队开发 以 RNA 为靶点的小分子药物，探索如何将基础研究真正转化为新的疗法。今天的节目我们聊一聊作为蛋白质结构预测工具的 AlphaFold3，它的突破与局限在哪里？RNA为什么是新一代药物的重要靶点？以及 AI 在新药研发中的作用究竟是什么? 本期人物 周耀旗，深圳湾实验室资深研究员，砺博生物科学创始人 Yaxian，「科技早知道」主播 主要话题 [02:42] 为什么蛋白质结构如此重要？解析蛋白结构是理解生命机器的关键 [05:47] 蛋白质结构预测简史（超硬核）：基于模板 --> 碎片拼接 --> 二面角+距离预测 [14:26] 「1+2=3」：AlphaFold 革命性飞跃的背后 [17:40] 结构生物学家会不会被替代？聊聊 AlphaFold 还做不了的事 [23:26] RNA 结构预测为何更难？仅4个碱基，结构不稳定，已知数据稀缺 [29:24] 蛋白质只是「提线木偶」，RNA 才是「操纵者」 [31:56] 从靶向蛋白到靶向 RNA -- HIV蛋白酶抑制剂的成功和 KRAS 蛋白的「光滑锁眼」的难题 [35:49] 靶向 RNA 药物的里程碑：首个靶向 RNA 的小分子药利司扑兰（Risdiplam） [38:50] 在缺乏结构数据的情况下，如何开发靶向 RNA 的药物？ [43:06] AI 在新药研发中的真实作用：是加速器，而非革命 [45:39] AI for Science：摆脱数据依赖，回归物理，寻找分子世界的「牛顿定律」 延伸阅读 AlphaFold 由谷歌 DeepMind 开发的人工智能程序，AlphaFold2 在精准预测蛋白质三维结构方面取得革命性突破而闻名。AlphaFold3 将其能力扩展到了 RNA、DNA 等更多分子。 CASP (Critical Assessment of protein Structure Prediction) 国际蛋白质结构预测竞赛，每两年举办一次，是评估和检验全球结构预测方法水平的「奥林匹克」 KRAS 一种重要的信号蛋白，其基因突变是多种癌症（如胰腺癌、肺癌）的关键驱动因素。由于其蛋白质表面光滑，缺乏明显的结合位点，长期以来被认为是「不可成药」的靶点。 SMN 蛋白 (Survival of Motor Neuron protein) 即运动神经元存活蛋白，该蛋白的缺失会导致 脊髓性肌萎缩症 (SMA)。全球首个靶向 RNA 的药物就是通过调控 SMN 的 RNA 来提高其蛋白水平。 PCC (Pre-clinical Candidate) 即临床前候选化合物，指在早期发现阶段后，被选定进入正式的临床前研究（如动物安全性、药代动力学试验）的药物分子 幕后制作 监制：Yaxian 后期：迪卡 运营：George 设计：饭团 商业合作 声动活泼商业化小队，点击链接直达声动商务会客厅（https://sourl.cn/9h28kj ），也可发送邮件至 business@shengfm.cn 联系我们。 加入声动活泼 声动活泼目前开放商务合作实习生、社群运营实习生和 BD 经理等职位，详情点击招聘入口详情点击招聘入口 (https://eg76rdcl6g.feishu.cn/docx/XO6bd12aGoI4j0xmAMoc4vS7nBh?from=from_copylink) 关于声动活泼 「用声音碰撞世界」，声动活泼致力于为人们提供源源不断的思考养料。 我们还有这些播客：声动早咖啡 (https://www.xiaoyuzhoufm.com/podcast/60de7c003dd577b40d5a40f3)、声东击西 (https://etw.fm/episodes)、吃喝玩乐了不起 (https://www.xiaoyuzhoufm.com/podcast/644b94c494d78eb3f7ae8640)、反潮流俱乐部 (https://www.xiaoyuzhoufm.com/podcast/5e284c37418a84a0462634a4)、泡腾 VC (https://www.xiaoyuzhoufm.com/podcast/5f445cdb9504bbdb77f092e9)、商业WHY酱 (https://www.xiaoyuzhoufm.com/podcast/61315abc73105e8f15080b8a)、跳进兔子洞 (https://therabbithole.fireside.fm/) 、不止金钱 (https://www.xiaoyuzhoufm.com/podcast/65a625966d045a7f5e0b5640) 欢迎在即刻 (https://okjk.co/Qd43ia)、微博等社交媒体上与我们互动，搜索 声动活泼 即可找到我们。 期待你给我们写邮件，邮箱地址是：ting@sheng.fm 声小音 https://files.fireside.fm/file/fireside-uploads/images/4/4931937e-0184-4c61-a658-6b03c254754d/gK0pledC.png 欢迎扫码添加声小音，在节目之外和我们保持联系。 Special Guest: 周耀旗.
Next-generation platforms and technologies are getting closer to cracking one of biopharma's biggest problems: delivering medicines, and mAbs in particular, to the brain. On the latest BioCentury This Week podcast, BioCentury's Selina Koch details the latest innovations in blood-brain-barrier shuttles and how the technologies could transform the treatment of neurological diseases.BioCentury's Lauren Martz discusses her conversation with Tony Wood, CSO of GSK, which included the pharma's strategy for indication expansion, why it prefers RNA modalities over AAV-based gene therapies, and how its quest for causal biology has evolved over the years.Washington Editor Steve Usdin discusses the first set of FDA's new commissioner's national priority review vouchers, and why the voucher program is unlikely to function as an incentive capable of steering future behavior. Usdin also discusses the potential impact of FDA staffing reductions on the sector. This episode of BioCentury This Week is sponsored by Evotec.View full story: https://www.biocentury.com/article/657326#BloodBrainBarrier #Neurology #DrugDelivery #MonoclonalAntibodies #RNAtherapeutics #CausalBiology #FDA00:01 - Sponsor Message: Evotec01:57 - Brain Shuttles13:57 - GSK Q&A20:08 - FDA VouchersTo submit a question to BioCentury's editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text
First up on the podcast, Contributing Correspondent Kai Kupferschmidt takes a trip to Svalbard, an Arctic archipelago where ancient RNA viruses may lie buried in the permafrost. He talks with host Sarah Crespi about why we only have 100 years of evolutionary history for viruses such as coronavirus and influenza, and what we can learn by looking deeper back in time. Next on the show, Nathalie Stroeymeyt, senior lecturer at the School of Biological Sciences at the University of Bristol, joins freelancer producer Elah Feder to talk about how humans aren't the only species that takes public health measures to stop outbreaks. To keep their colonies healthy when threatened with infectious disease, ants socially distance and even make architectural changes to their nests' organization. This week's episode was produced with help from Podigy. About the Science Podcast Learn more about your ad choices. Visit megaphone.fm/adchoices
© 2020-2025 Ivy Podcast Discovery LLC
